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1Chapter 1
Introduction
2Solid cancers and treatment
Cancer is becoming the leading cause of death in the world and gaining
impact fast in developing countries [1, 2], of which solid tumors are a
significant part. Unlike normal tissue or organs, solid tumors are poorly
structured as a result of fast proliferation of cancer cells, leading to an
abnormal vasculature system. Tumor-associated vasculature exhibits a
lack of hierarchical branching in which the recognizable features of
arterioles, venules and capillaries are lost. The vessels are tortuous and
unevenly dilated. Therefore, tumor blood flow is chaotic, can be
stationary and even change direction of flow [3]. This results in interstitial
hypertension, hypoxia, hypoperfusion and acidosis in solid tumors.
Together, the factors cause solid tumor to have a complex
microenvironment and provide unique biochemical and physiological
properties, which cause barriers to treatment of solid cancers.
Classical cancer therapies widely used in the clinic include surgical
intervention, radiotherapy and chemotherapy or a combination of these
options. Surgery, used to prevent or lower the risk of developing certain
types of cancer, is a common option in cancer treatment. Surgery is most
effective when completely removing cancerous tissues that are at an early
stage and have not spread to other parts of the body. However, in some
cases, cancer tissue are not possible to be removed by surgery because of
patient’s health state or vital organs involved [4, 5]. Often radiotherapy
or/and chemotherapy are given when surgery is not applicable or not
necessary. Radiotherapy relies on the high doses of radiation to damage
the DNA, thereby killing cancer cells. The cancer cells are less capable of
recovering from the damage induced by radiation compared to healthy
cells. But the side effects induced by radiation can limit the dose and may
induce a secondary cancer. Besides, the lack of enough oxygen in solid
tumors also affect the efficacy of radiotherapy as molecular oxygen is a
potent radiosensitizer [6]. Chemotherapy is another important treatment
option for cancer (Table 1). It makes use of cytotoxic agents to attack
rapidly proliferating cells such cancerous cells, thus suppressing cancer
3development [7]. However, some healthy cell types have fast proliferating
rates as well, including bone marrow cells, intestinal cells and hair
follicles, hence these toxic agents can cause severe side effects in those
healthy tissues. In addition, due to that most cytotoxic compounds are not
that selective and administrated in a free form, conventional
chemotherapy requires a high dose to reach a therapeutic concentration at
tumors. Together with the often large volume of distribution, meaning
that the drug ends up in most parts of the body, leads to dose-limiting and
possibly life-threatening systemic toxicity. For instance, doxorubicin
(DXR), an anthracycline, has a wide antitumor spectrum which is one of
the most widely used chemotherapeutic drugs for cancer treatment [8].
DXR can effectively kill cancer cells by intercalating with DNA, but its
severe myelosuppression and cardiotoxicity limits the clinical use when
giving in a free form. Idarubicin, another anthracycline drug, has been
reported with the same antitumor mechanism but less cardiotoxicity and
higher cytotoxicity compared to DXR [9, 10]. However, the short
circulation time of IDA in blood hardly leads to effectiveness in most
solid tumors but induces side effects in healthy tissues [11], which is used
only as a second-line chemotherapeutic drug for leukemia in the clinic at
present [12, 13].
Another hot therapy for cancer nowadays is immunotherapy, including
the application of immune checkpoint inhibitor (e.g. PD 1/PD-L1
inhibitor) and adoptive T cell transfer (e.g. Car-T and TCR-T) [14, 15].
Cancer immunotherapy aims to activate or enhance the ability of the host
immune cells against tumor (e.g. blocking the immunosuppression in
tumor or modifying T cells), thus specifically killing cancer cells. This is
expected to reduce side-effects resulted from conventional radio-
/chemotherapy. Immunotherapies showed promising efficacy on some
patients, however the extremely high cost (over $200,000/year per patient
[16, 17] ) and limited cancer type that can be beneficial from
immunotherapy, make cancer immunotherapy difficult before it can be
widely applied in the clinic.
4These conventional therapies are not cancer specific and expose a risk to
patients because of the side effects on healthy tissues. Because of these
reasons, novel and more targeted therapies on cancer treatment are
necessary to be investigated.
Table 1. Examples of commonly used chemotherapeutics in the clinic
Types of commonly used
chemotherapeutics
Examples
Alkylating agents Cisplatin, Melphalan, Ifosfamide
Alkaloids Vincristine, Paclitaxel, Tenisopide
Antitumor antibiotics Doxorubicin, Mitomycin, Idarubicin
Antimetabolites Methotrexate, 5-Fluorouracil, Gemcitabine
Liposomal chemotherapy for solid cancers treatment
Due to the severe systemic toxicity induced by traditional
chemotherapeutic drugs to healthy tissues, nano-sized drug carriers are
developed to encapsulate cytotoxic compounds. Liposomes have been one
of the best studied drug delivery systems used in cancer treatment since
the1970s [18]. Liposomes are potent biocompatible nano-sized carriers,
composed of different phospholipids with or without cholesterol, forming
hollow vesicles with aqueous core and hydrophobic bilayer (Figure 1),
which can load chemical compounds, genetic materials and contrast
agents for delivery [19]. Nowadays there have been many liposomal
products with size at around 100 nm either commercially available or
under clinical trials [20]. After encapsulation by these liposomes,
cytotoxic compounds avoid the direct contact with healthy tissue during
delivery and circulate longer when liposomes are coated with a
polyethyleneglycol (PEG). It is believed, although quite under debate,
5that chemotherapeutic compounds accumulate more in tumors based on
the enhanced permeability and retention (EPR) effects [21, 22] as a result
of the loose and chaotic structure of tumor vasculature, which leads to
gaps between endothelial cells that allow these nanoparticles to passively
accumulate in tumoral interstitial space [23].
Figure 1. schematic representation of a liposome. The liposome is a
hollow vesicle with aqueous core and hydrophobic phospholipid bilayer.
The liposomal bilayer consists of different phospholipids and cholesterol
can be added. Hydrophilic drugs can be encapsulated inside aqueous
compartment and hydrophobic compounds can be loaded in the bilayer.
A well-known and most widely used liposomal chemotherapeutic is
Doxil® (Caelyx® in Europe), a pegylated liposome with size at 90 nm
encapsulating DXR approved by the FDA in 1995 [24]. DXR is loaded
into liposomes by a pH or ion gradient [25, 26], which is also called
active loading or remote loading. Here the liposome aqueous core has an
excess of protons relative to the external media that makes DXR
6protonate when entering the liposome. Exceeding a certain interior
concentration, protonated DXR will precipitate and crystallized with
anions inside the core liposomes (Figure 1). This DXR liposome
formulation reduces the systemic side effects and prominently prolongs
the circulation half-life of DXR from minutes when given in free form to
21-54 hours after administered in patients [27, 28], which leads to an
increased accumulation in tumors compared to free drugs [29, 30].
However, Doxil® causes new dose limiting side effects, including palmar-
plantar erythrodysesthesia and stomatitis, which are related to the passive
accumulation of pegylated liposomes in the skin especially at hands and
feet during the prolonged blood circulation time, where DXR is slowly
released resulting in local toxicity [24]. Besides, Doxil® shows slow DXR
release from liposomes to cause a limited bioavailable drug concentration
exposed to tumor cells due to the stable liposome carrier, which impedes
the anti-cancer activity [30, 31]. Though the liposomal product shows
improved efficacy in some solid tumors such as Kaposi sarcoma and
ovarian cancer [24], due to the complex microenvironment and chaotic
vasculature between tumor types and within patient populations the
extravasation level of nanoparticles from tumor vessels can be
significantly different and limited [23, 32, 33]. More importantly, the
majority of tumor vasculature is not desirably developed, causing limited
perfusion and even blocked vessels in tumor. Together, these result in
insufficient drug level in tumor when applying these conventional
liposomes for solid tumor treatment. Therefore, to improve treatment in
solid tumors, strategies that can elevate drug delivery and facilitate drug
uptake by tumor cells more site-specifically and efficiently is required.
Mild hyperthermia
Hyperthermia has been used alone or as a combination to treat tumors in
the clinic for years [34-37]. For example, RFA (radio frequency ablation),
a solid tumor treatment strategy used in the clinic, causes cell death by
7inducing a local high temperature up to 100°C in tumor tissue [38]. In a
combination therapy, mild hyperthermia (40-44°C) can be clinically
utilized as an adjuvant to the radiotherapy or chemotherapy, generating
synergistic effects and enhancing therapeutic effect of these treatments
[34]. Mild hyperthermia (HT) benefits the chemotherapy in multiple ways.
HT can increase blood flow, thus facilitating the perfusion of
chemotherapeutic compounds inside tumor [39, 40]. Furthermore, mild
hyperthermia improves the permeability of tumor vessels to small
molecules and nanoparticles by broadening the gaps between the
endothelial cells in tumor vessels, which improves drug accumulation in
tumor tissues [41-43]. Li and colleagues have shown that extravasation of
liposomes from tumor vessels was increased under mild hyperthermia,
compared to non-tumor vessels at which HT hardly showed improved
extravasation [44, 45]. And also HT can inhibit DNA repairs and sensitize
cancer cells to chemotherapy [34, 46, 47]. Krawczyk et al. reported that
using local mild hyperthermia at 41-42.5°C inhibits homologous
recombination – one major pathway for DNA double strand breaks
repairing which reduces the effectiveness of chemotherapy and
radiotherapy [48].
Another function of mild hyperthermia in combination treatment is used a
trigger for heating responsive release drug delivery systems. Local heat-
triggered drug carries can produce a site-specific release and a high drug
concentration at heated areas, e.g. tumor, thus facilitating drug molecules
infusion and penetration in tumor tissue, and increasing the tumor cell
uptake and reducing drug level in non-heated sites. At present, several
methods have been reported to generate local hyperthermia, including
using alternating magnetic field (AMF) [49], near-infrared laser [50] and
high-intensity focused ultrasound (HIFU) to trigger drug release locally
[51].
8Thermosensitive liposomes
Designing drug delivery carriers which are able to controllably release
content by environmental stimuli is of great significance for achieving a
high drug level at disease sites. Thermosensitive liposomes (TSL) receive
more attentions due to the advantages that it is relatively easy to set up
external heating equipment facilitating drug release at mild hyperthermic
temperatures, and obtain a timely and rapid release only at the heated area
(e.g. tumor), thus providing enhanced drug delivery to tumor. When
designing a thermosensitive liposome, the selection of phospholipids is
crucially important as it determines the preferred temperature for drug
release [52]. The liposome membrane consisted of ideally mixed
phospholipids has a melting temperature (Tm) at which the lipid bilayer
undergoes a phase transition from a solid gel phase to a liquid crystalline
phase and thus improves the permeability of liposomal membrane (Figure
2). When temperature below Tm, the bilayer is in solid gel state and
phospholipid molecules arrange orderly and tightly, forming an immobile
and impermeable membrane. When heating the liposomal membrane
around Tm, the lipid molecules at grain boundary regions of membrane
begin to melt into liquid state but others remain in solid gel phase [53, 54],
which creates many “gaps” resulted from disordered arrangement of lipid
molecules between two phases, thereby leading to rapid and massive drug
release from aqueous core of liposomes. When further increasing
temperature to greatly exceed Tm, the whole liposome membrane is into
liquid crystalline state and the “gap” between solid and liquid phase is not
presented anymore, which causes reduced permeability of membrane and
thus drug release is decreased [55].
9Figure 2. Schematic representation of liposomal membrane permeability
states at different temperatures. (a) When below Tm, liposomal
membrane is in solid gel phase and lipid molecules stand orderly and
tightly, leading to minimal space lipid molecules for content release. (b)
When approaching Tm, liposomal membrane undergoes a phase transition
generating co-existence of solid phase and liquid phase, which causes
disordered arrangement of lipid molecules between these two phases and
results in maximum space for release drug. (c) When T beyond Tm,
liposomal membrane is in liquid phase and all lipid molecules are more
ordered standing than state at Tm, space between lipid molecules is
decreased and membrane permeability to drug is reduced.
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Thermosensitive liposomes were first proposed by Yatvin in 1978 [56],
who demonstrated the heat-triggered release of carboxyfluorescein or
neomycin when using DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine; Tm 41°C) and DSPC (1,2-distearoyl-sn-glycero-3-
phosphocholine; Tm 55°C) at 3:1 molar ratio to form TSL. However, the
release rate was slow and stability was poor due to the immatural
formulation at that time, leading to the suboptimal effectiveness. In the
decades that followed, thermosensitive liposomes have been further
developed and used for cancer chemotherapy, showing and improved
cancer cell killing. Pegylation and cholesterol were introduced into
thermosensitive liposomes which is termed traditional thermosensitive
liposomes (TTSL), showing enhanced circulation time and stability at
body temperature [57, 58]. However, considering the short transition time
of liposomes passing the heated tumor areas, the release from TTSL was
still not fast enough and the overall Tm of liposome was too high.
Needham and Dewhirst proposed a new formulation, namely
ThermoDox®, which applied lysolipid instead of cholesterol and DSPC in
their thermosensitive liposome composition [59]. Lysolipids form micelle
and generate pores in liposomal membrane at Tm, thus leading to a higher
content release [60, 61]. Yet lysolipid also reduces the liposome stability,
which causes higher drug leakage at body temperature during delivery [62,
63]. Tagami et al. applied Brij surfactants to replace lysolipid and PEG-
lipid in liposomes which maintain the fast release kinetics but increase
liposome stability [64]. Similarly, Lindner et al. reported a novel
phospholipid, DPPG2 (1,2-dipalmitoyl-sn-glycero-3-
phosphoglyceroglycerol) added in TSL composition, showing improved
stability without affecting thermosensitivity for drug release [65]. Li et al.
reported thermosensitive liposomes consisted of DPPC, DSPC and 5
mol% PEG-lipids can perform similarly rapid drug release and keep the
improved stability at physiological temperature when tested in serum
medium [66].
These above developed thermosensitive liposomes all have shown
significantly improved chemotherapy efficacy due to the locally effective
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release of cytotoxic compounds in tumor areas compared to non-
thermosensitive liposomes in several tumor models. Interestingly, to date
it seems that doxorubicin has been used as the only drug candidate for
thermosensitive liposome encapsulation in most literature reports. Apart
from the fluorescent and easy loading properties of doxorubicin,
doxorubicin shows effectiveness in several cancers when used in free
form before, which probably makes people assume that DXR should still
be the best option for thermosensitive liposomes encapsulation when
treating these tumors. Despite thermosensitive liposomes offering a fast
release of doxorubicin in tumor sites, the uptake rate of DXR by tumor
cells may be not optimal due to its hydrophilicity, which may limit
efficacy of DXR-TSL. For a successful thermosensitive liposome as a
drug delivery system, besides desired stability at body temperature and
rapid release under hyperthermia, the fast cellular uptake of released drug
molecules is also crucially important. Therefore, selection of proper drugs
and thermosensitive liposomes to reach the optimal release performance
and treatment effectiveness will be investigated in this thesis.
Aim of the thesis
This thesis aims to describe the use of DPPC-DSPC based
thermosensitive liposome in combination with local mild hyperthermia to
improve better chemotherapy efficacy from 2 parts: 1) what is the proper
drug to be encapsulated in TSL, 2) what is the mechanism of our TSL
rapid release and how to reach optimal release formulation.
Topics of the thesis
Chapter 2 describes the development of a novel thermosensitive
liposome formulation loading with a new drug – Idarubicin (IDA), an
anthracycline similar to doxorubicin but more hydrophobic. This IDA-
TSL was optimized and tested in vitro and in vivo. Its stability at body
temperature, triggered release at mild hyperthermia and efficacy in tumor
response were investigated.
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Chapter 3 further investigates IDA and DXR as loaded drugs, which are
different in hydrophobicity, encapsulated in TSL. Deep and quantitative
comparison of IDA-TSL and DXR-TSL were performed with regard to
their in vitro release kinetics and cellular uptake and retention, in vivo
circulation and distribution, real time release profiles inside tumor during
HT and post HT, intratumoral distribution and accumulation of released
IDA and DXR, and efficacy in tumors. This work is to understand how to
choose the best drug for thermosensitive liposome-mediated delivery
systems.
Chapter 4 deeper describes the mechanism of rapid release at Tm of
DPPC-DSPC based thermosensitive liposome. Carboxyfluorescein was
used as a model drug loaded inside TSL composited of different ratios of
DPPC and DSPC, indicating the proper composition generates a maximal
grain boundary density, thus leading to a maximum release.
Chapter 5 searches for a proper release equation to describe release
profiles of thermosensitive liposomes, especially at Tm. Several
commonly used mathematic models were tested and a new empirical
equation was established, which shows the better fitting effect for release
at Tm and non-Tm.
Chapter 6 discusses the results of the studies and reviews the current
status of thermosensitive liposome mediated drug delivery with HT.
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Abstract
Drug delivery through thermosensitive liposomes (TSL) in combination
with hyperthermia (HT) has shown great potential. HT can be applied
locally forcing TSL to release their content in the heated tumor resulting
in high peak concentrations. To perform optimally the drug is ideally
released fast (seconds) and taken up rapidly by tumor cells. The aim of
this study was to develop a novel thermosensitive liposome formulation
of the anthracycline idarubicin (IDA-TSL). The hydrophobicity of
idarubicin may improve its release from liposomes and subsequently
rapid cellular uptake when combined mild hyperthermia. Here, we
investigated a series of parameters to optimize IDA-TSL formulation. The
results show that the optimal formulation for IDA-TSL is
DPPC/DSPC/DSPE-PEG (6/3.5/0.5 mol%), with ammonium EDTA of
6.5 pH as loading buffer and a size of ~85 nm. In vitro studies
demonstrated minimal leakage of ~20% in FCS at 37°C for 1 h, while an
ultrafast and complete triggered release of IDA was observed at 42°C. On
tumor cells IDA-TSL showed comparable cytotoxicity to free IDA at
42°C, but low cytotoxicity at 37°C. Intravital microscopy imaging
demonstrated an efficient in vivo intravascular triggered drug release of
IDA-TSL under mild hyperthermia, and a subsequent massive IDA
uptake by tumor cells. In animal efficacy studies, IDA-TSL plus mild HT
demonstrated prominent tumor growth inhibition and superior survival
rate over free IDA with HT or a clinically used Doxil treatment. These
results suggest beneficial potential of IDA-TSL combined with local mild
HT.
Keywords:
Thermosensitive liposome, idarubicin, triggered drug release, mild
hyperthermia
23
1. Introduction
One of the major challenges of current available chemotherapeutic agents
used in conventional or combination therapy for cancer is reducing
considerable side effects while improving intratumoral delivery [1-2]. For
instance, anthracycline antibiotics, especially doxorubicin (DXR),
represent one of the most widely used anticancer drugs, but also are of
limited benefit to cancer patients because of severe cardiotoxicity and
myelosuppression [3,4]. Nanosized liposomes receive increasing interest
due to their ability to reduce drug side effects on normal tissues and
prolong its retention in circulation. Besides, high intratumoral
accumulation of these drug-loaded liposomes also improves antitumor
activity because of the EPR (enhanced permeability and retention) effect
[5]. Several liposomal formulations have been approved [6-9], among
which Doxil® (Caelyx® in Europe) is the most well-known and widely
used chemotherapeutic liposome. This DXR-loaded liposome exhibits
reduced side effects and prolonged half-life in vivo. However, Doxil®
does not show much improvements in efficacy mainly attributed to the
slow drug release and the lack of tumor specific targeting, which hinders
its therapeutic efficacy [10].
In 1978, Yatvin et al. proposed the concept of temperature-sensitive
liposomes which could generate content release at phase transition
temperature (Tm) by using mild hyperthermia (HT) [11]. The initial
thermosensitive liposomes were composed of
dipalmitoylphosphatidylcholine (DPPC) alone or with
distearoylphosphatidylcholine (DSPC) with a Tm range from 42.5-44.5°C
[11,12]. However, slow release rate of encapsulated drug, and at that time
difficulty to apply hyperthermia locally, limited its application [11,13].
To improve release kinetics Needham et al. used lysolipids which have
low Tm (e.g. monopalmtoylphophatidylcholine (MPPC) or
monostearoylphosphatidylcholine (MSPC)), lipid-grafted PEG and DPPC,
to create a new, low temperature sensitive liposomal DXR formulation
(DXR-LTSL) [14-16]. This formulation, commercially named
ThermoDox® (currently in phase III clinical trials [17]), demonstrates
substantial drug release in a matter of seconds at around 39-41 °C.
Nevertheless, DXR-LTSL is less stable at physiological temperature,
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exhibiting high leakage of ~50% within 1 h [18-20]. Recently, a series of
further optimized doxorubicin thermosensitive liposome (DXR-TSL)
formulations have been reported, showing desired triggered release by
mild HT and favorable stability at physiological temperature [18, 21-23].
In contrast to classic liposomes, which are believed to rely on the EPR
effect to accumulate in tumor tissue, TSL can also be used to achieve so-
called intravascular release [24]. As soon as a TSL enters the heated
region rapid release is enforced resulting in a high local peak
concentration. To enable maximum performance the released drug should
rapidly enter tumor cells before washout. In this application TSL stability
is of lesser importance compared to passive accumulation, while rapid
release is crucial, indicating that other chemotherapeutics with more
favorable kinetics than doxorubicin could be used. The intravascular
release also enables the treatment of mircometastasis surrounded by non-
leaky vessels. With the integration of imaging technologies such as MRI
and hyperthermia smaller and multiple tumors can be heated and treated
[24], which makes this approach more useful for metastatic disease
creating possibilities for new drug-TSL formulations.
DXR has been investigated in various liposomal formulations owing to its
wide antitumor activity and active loading ability, and handy fluorescence
detection property [25]. By contrast, idarubicin (IDA), another
anthracycline anticancer drug, which is more hydrophobic and
structurally similar to DXR [26,27], receives lesser attention in liposomal
nanoparticles. However, IDA has less cardiotoxicity than doxorubicin
[26]. Although currently this drug is approved primarily for the treatment
of acute and chronic myelogenous leukemia, and acute lymphoblastic
leukemia, etc. [28,29], IDA also displays anti-tumor activity in melanoma,
sarcoma, lung, ovarian and breast cancers [30]. IDA has a similar
anticancer mechanism of action to other anthracycline drugs, by
interfering with DNA synthesis [31]. It is worth to note that IDA is five to
ten times more potent than daunorubicin and doxorubicin in some studies
[32-34]. Additionally, idarubicinol, the metabolite of IDA, exhibits
antitumor effects comparable to IDA [34,35]. More importantly, IDA
shows less sensitivity to the activities of P-gp and multidrug resistant
proteins [36,37]. These reports indicate the potential of an improved
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effectiveness compared to DXR-liposome when IDA is encapsulated in
liposomes.
Nevertheless, a few IDA liposomal formulations have been reported to
date [30,38-40]. Dos Santos et al. show rapid leakage of IDA when
encapsulated in cholesterol-containing liposomes [40]. They thought that
for IDA-like hydrophobic drugs, decreasing the interactions between the
drug and liposomal membrane is more important, suggesting that using
cholesterol-free liposomes is beneficial to decrease leakage of IDA [30].
While, Gubernator et al. recently developed a new method to load IDA by
applying EDTA ion gradient instead of conventional sulfate and citrate
gradients, forming a more stable drug precipitate in liposomes, which
exhibited desirable stability in plasma even if cholesterol-containing
liposomes are used [39]. The authors concluded that the formation of
stably insoluble drug precipitates inside liposomes can lead to increased
drug retention equally [39].
However, the above IDA formulations are conventional liposomes, and
there is no thermosensitive liposome formulation for IDA so far. In
previous work, we have attained several favorable DXR-TSL
formulations which revealed minimal leakage at 37 °C and fast release at
42 °C in 100% FCS in in vitro tests [18,41,42]. Therefore, in this study,
we developed and optimized a novel IDA-TSL formulation to improve
IDA retention at 37 °C and rapid release at 42 °C. The IDA-TSLs were
characterized from in vitro and in vivo.
2. Materials and methods
2.1. Materials
1,2-dipalmitoyl-sn-glycero-3-phosphcholine (DPPC), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG) were provided by Lipoid
(Ludwigshafen, Germany). PD-10 columns were obtained from GE
Healthcare (UK). Idarubicin hydrochloride, cholesterol and other
chemicals were purchased from Sigma Aldrich unless otherwise specified.
2.2. Preparation of TSLs
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TSLs were mainly composed of DPPC/DSPC/DSPE-PEG in various
molar ratios (see Table 1.) by using the thin lipid film hydration method,
followed by heated extrusion [18]. Briefly, 100 µmol of lipids was
dissolved in methanol/chloroform (1/9 v/v) mixed solvent which was then
evaporated at 40°C, followed by nitrogen flush for 30 min to remove
residual solvent. The resulting dried lipid film was hydrated with
appropriate solutions of sodium citrate (300 mM, pH 4.0), ammonium
sulfate (250 mM, pH 5.5), ammonium oxalate (250 mM, pH 5.5) or
ammonium EDTA (300 mM, pH 4.5-6.5) at 60°C (see Table 1.).
Additionally, thermostable liposomes (DSPC/DSPE-PEG: 9.5/0.5) were
prepared as comparison with TSLs. Small unilamellar vesicles were
obtained by extrusion through Nuclepore® (Whatman Inc., USA) filters
with pore sizes from 50-200 nm on a Thermo barrel extruder at 65°C
(Northern Lipids, Canada). Diameter and polydispersity index (PDI), as
well as zeta potential were measured by using Zetasizer Nano-ZS
(Malvern Instruments Ltd., UK).
2.3. Preparation of ion gradients for IDA encapsulation into TSLs
PD-10 column was used to change the external solution of TSLs to
HEPES buffer (150 mM NaCl, 20 mM HEPES, pH 7.4) in order to
produce the ion gradients. Lipid concentration was then measured by
phosphate assay [43] for subsequent quantitative IDA encapsulation.
Loading IDA into TSLs was performed similar to DXR-loading process
[18]. Briefly, TSLs with low pH or high ammonium concentration inside
were mixed with HEPES buffer (pH 8.5 or 9.5) and IDA according to a
molar drug/lipid ratio of 0.15/1 (0.3/1 or 0.45/1 for individual
formulations), followed by co-incubation at 37°C for 40 min at a speed of
800 rpm in a thermal shaker (Eppendorf Thermomixer, the Netherlands).
As anthracyclines are relatively unstable at high pH IDA loading should
be performed within the time-frame given, during which we observed no
reduction in IDA activity [44]. The IDA-loaded TSLs were collected by
ultracentrifugation (Beckman Coulter, US) at 40,000 rpm for 2 h at 4°C,
following by resuspension in HEPES buffer (pH 6.5) overnight at 4°C.
Phosphate assay was performed again to quantify the drug to lipid ratio.
2.4. Cryo-TEM images of IDA-TSLs
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IDA-TSL consisting of DPPC/DSPC/DSPE-PEG (60/35/5, mol/mol) by
using ammonium EDTA gradient (pH 6.5) with a drug/lipid ratio of 30
mol% was prepared. Cryo-transmission electron microscopy (cryo-TEM)
images of IDA-TSL were captured via a Fei Tecnai F30ST microscope
(Philips, the Netherlands) according to the methods described previously
[42]. Briefly, 3 µl of IDA-TSL suspension was dropped on a lacy carbon
film and subsequently snap-frozen in liquid ethane by a Vitro bot. An
amorphous ice film was created, containing particles of interest.
2.5.In vitro IDA-TSL stability and release kinetics in 100% FCS
2.5.1. Time-dependent release
To determine the in vitro stability of IDA-TSL, 50 μl of 8 mM [lipid]
IDA-TSL suspension was added into 2.95 ml 100% fetal calf serum (FCS)
in a quartz cuvette at 37°C for 1h. Real-time leakage of IDA was detected
with a water bath combined spectrofluorometry (Ex. 485 nm/Em. 571 nm,
Ex. slit 5 nm/Em. slit 10 nm) (Hitachi F-4500 Fluorescence
Spectrophotometer, Japan).The average fluorescence intensity of the
initial 5 seconds was recorded as I0 of IDA-TSL leakage, while
fluorescence was measured as It at a certain time point. After 1h,
detergent (10% Triton X-100) was used to disrupt all liposomes to
measure maximal IDA fluorescence, which was recorded as Imax. Leakage
(%) = (It - I0)/(Imax - I0)× 100. Release of IDA-TSL at 42°C was performed
similarly.
2.5.2. Temperature-dependent release
Temperature-dependent release was performed by adding 50 μl of 8 mM
[lipid] IDA-TSL suspension into pre-heated 2.95 ml of 100% FCS in a
quartz cuvette. This cuvette was then incubated for 5 min at temperature
ranges (from 25°C, 30-45°C), followed by adding detergent to obtain
maximal fluorescence. The temperature-dependent release (%) was
calculated in the same way described above (2.5.1.), but using the
fluorescence intensity measured at 25°C for calibration.
2.6. In vitro IDA-TSL cytotoxicity assay
Murine B16BL6 melanoma and human BLM melanoma cells were
cultured in DMEM medium (containing 4500 mg glucose/L, L-alanyl-L-
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glutamine) with 10% FCS, and murine C26 colon carcinoma cells were
cultured in RPMI-1640 medium (containing L-alanyl-L-glutamine) with
10% FCS. Based on the results in 2.5, cytotoxicity assays were performed
with the optimal IDA-TSL formulation. B16BL6, C26 and BLM cells
were seeded in 96 well-plates at a density of 1500 cells/well, and placed
in an incubator (37°C, 5% CO2) for 24 h. IDA-TSL, free IDA and empty
TSL were diluted from stock solutions in cell culture medium and filtered
through 0.45 µm filters. These three resulting solutions, subsequently,
were exposed to heating at 37 or 42°C for 15 min in a water bath,
followed by 5-times dilution with cell medium into 9 continuous
concentrations. After adding samples to the cells, the 96 well-plates were
incubated for 72 h directly, or for 1 h followed by 3-times wash and
treated with fresh medium for an additional incubation of 72 h. Cell
survival rates were measured by using the colorimetric SRB assay
described by Vichai et al. [45]. IC50 (50% cellular growth inhibition) was
calculated and presented.
2.7. Flow cytometry and in vitro live cell imaging
To confirm in vitro activity of IDA-TSL systems on live cells, several
IDA-TSL formulations were tested: IDA-TSL with 80, 70, 60, or 50%
DPPC, loaded with citrate buffer, and compared to free IDA and cell
medium. BLM cells in full FCS were exposed to the different
formulations for 30 min at 37 or 42°C, at an IDA concentration of 20
μg/ml (3 ml for flow cytometry, cells growing in T25 flask; 1 ml for cell
confocal imaging, cells growing in 12-well-glass-bottom-plate).
Thereafter cells were washed and harvested by trypsinization, followed
by flow cytometry. For each sample 50,000 cells were analyzed by flow
cytometer on a BD FACS CantoTM. For confocal laser scanning
microscope (CLSM) cells were washed and fresh medium added,
followed by confocal imaging (Zeiss LSM 510 META, Germany) using a
helium-neon laser (Ex. 543 nm, Em. LP 560 nm). Images with higher
magnifications were captured to visualize IDA uptake by cells.
2.8. Mouse tumor models
NMRI nu/nu mice were purchased from Harlan and housed at 20-22°C,
humidity of 50-60%, and 12 h light-dark cycles. Sterile rodent food and
acidified vitamin C-fortified water were offered ad libitum. Eight-week
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old mice with weight of 40-45 g (NMRI nu/nu) were chosen for
experiments. Mice (C57BL/6) with constitutive vascular endothelial cell
expression of an eNOS-Tag-GFP fusion protein were developed by Dr. R.
de Crom and R. van Haperen, Department of Cell Biology, Erasmus MC,
Rotterdam, the Netherlands, bred in house and used for intravital
microscopy experiments. All animal studies were performed according to
protocols approved by the committee of Animal Research of the Erasmus
MC, Rotterdam, the Netherlands.
B16BL6 cells (~106) were injected subcutaneously in the flank of a
C57BL/6 mouse to grow a tumor bulk with a diameter of circa 1 cm. A
small piece of this tumor (~1 mm3) was then transplanted into the fascia
of a dorsal skin flap placed in a window chamber on the mouse [18].
These window chambers-bearing mice were housed individually at 30°C
with 70% humidity. Experiments commenced when diameters of tumors
reached approximately 5 mm in the dorsal skin flap window chamber.
For in vivo efficacy study, a tumor piece (~3 mm3) of BLM melanoma (6
mice/group) were transplanted subcutaneously in the hind leg of NMRI
nu/nu mice. When tumors reached around 100 mm3 in size, mice were
used for efficacy experiments.
2.9. In vivo IDA-TSL release by intravital microscopy
In vivo IDA-TSL release was observed by intravital fluorescence
microscopy. Mice were anesthetized with isofluorane (Nicholas Piramal,
UK) on a thermal plate at 37°C during the whole experimental process.
An external circular conductive heating coil was attached to the glass at
the back side of window chamber to provide homogenous local HT [18].
Thermocouples (point-welded thin manganese and constantan wires from
Thesso®, Amsterdam) were imbedded in the window chamber for online
monitoring of temperature in the tumor tissue. IDA-TSL (4 mg/kg) was
injected intravenously through the tail vein.
Regions of interest were observed by CLSM. Image acquisition of
background was handled before IDA-TSL injection. Initial images were
captured as before mild HT within 10 min post-injection, and then the
window chamber tissues were heated to 42°C and maintained for 1 h.
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Release of IDA-TSL was monitored online by a helium-neon laser (Ex.
543 nm, Em. LP 560 nm), and endothelial cells were visualized by an
argon laser (Ex. 488 nm, Em. BP 505-550 nm). Intermittent images were
taken every 10 seconds during heating at 42°C. Images with higher
magnifications were captured at the end of experiments to visualize IDA
uptake by tumor cells. CLSM image software (Zeiss, Germany) was then
used to analyze these collected images.
2.10. Therapeutic efficacy
Mice bearing subcutaneously tumor size of around 100 mm3 (Length ×
Width × Depth × 0.4) in their right hind legs were anesthetized and
prepared for local mild HT [18]. Briefly, the skin and foot surrounding
tumor in right legs were covered in Vaseline cream to protect normal
tissue from heating damage. The hind tumor-bearing legs were placed
inside a water bath (tumor temperature at 42°C) and kept at a steady
position during the HT treatment. When tumor temperature reached 42°C,
IDA-TSL, free IDA and saline were administered at 1.5 mg/kg (IDA)
through i.v. injection. The tumor temperature was maintained at 42°C for
1 h. Normothermia (NT) mice treated with IDA-TSL, free IDA and
saline at the same doses were maintained at 37°C for 1 h as comparison.
Doxil was used here to mimic clinic application as comparison by giving
a first dose of 4.5 mg/kg and 3 times a dose of 1 mg/kg at an interval of 4
days. Tumor size was measured every day after treatment. Mice were
euthanized when tumor reached ~15x15x15 mm3 in size or based on
human endpoint.
2.11. Statistical analysis
In vitro and in vivo data were analyzed using Mann Whitney U test or
Kruskal Wallis test when appropriate. P values below 0.05 were
considered significant.
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3. Results
3.1. In vitro characterization of IDA-TSLs
The IDA-TSLs described here were of uniform diameter of ~85 or ~130
nm (respectively designated small and large) with PDI values below 0.1.
IDA could be encapsulated with an efficiency of around 100% (Table 1).
3.1.1. The influence of loading buffers on IDA-TSL stability
Several buffers are used in the literature to load doxorubicin or idarubicin
in liposomes. Here sodium citrate, ammonium sulfate, ammonium oxalate
and ammonium EDTA salt solutions, were selected to load IDA
(formulation 1-4 in Table 1). When sodium citrate or ammonium sulfate
was applied, leakage up to ~43% to ~50% was observed within 1 h-
incubation in 100% FCS at 37°C. Maximal release at 42°C was reached
within a few seconds (Figure 1A,B). Also using ammonium oxalate as
loading buffer resulted in instable liposomal formulation of IDA with a
leakage of circa 40% at 37°C. Rapid heat triggered drug release was
observed at 42°C, similar to ammonium sulfate IDA-TSL (Figure 1C). By
contrast, loading IDA using ammonium EDTA showed a significantly
lowered leakage to ~23% at 37°C. Rapid and maximum release was
maintained at 42°C (Figure 1D). Hence, ammonium EDTA solution was
selected as the optimal loading buffer for the following IDA-TSL
formulations.
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Figure 1. The influence of loading buffer on idarubicin (IDA) release
from 85 nm IDA-TSL at 37°C (blue) and 42°C (black) in FCS for 1 h.
The loading buffer was sodium citrate pH 4.0 (A), ammonium sulfate pH
5.5 (B), ammonium oxalate pH 5.5 (C) or ammonium EDTA pH 5.5 (D).
Liposome composition was DPPC/DSPC/DSPE-PEG: 7/2.5/0.5. (Three
independent tests were performed. A representative release profile is
shown.)
3.1.2. The influence of liposome compositions on IDA-TSL stability
Cholesterol is used to increase stability of liposomal membranes and
improve enclosure of contents [46]. Therefore we added cholesterol to
IDA-TSL formulation for further optimization (formulation 5 in Table 1).
For the same purpose, paraffin, the most lipophilic molecule, was used to
formulate IDA-TSL (formulation 6 in Table 1). Nevertheless, both
cholesterol and paraffin did not improve IDA-TSL stability showing
around 30% leakage at 37°C (Figure 2A). Interestingly, these two
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formulations demonstrated decreased release rates at 42°C, reaching
maximum release after ~10 min (Figure 2A).
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Table 1. Characterization parameters of IDA-TSL used in this study. Mean±SD, N=3.
Liposomes
composition
(mole)
Ion gradient Particle size (nm) Polydispersity index Drug/lipid
(mole/mole)
Leakage
(%) at 37℃
in 100%
FCS
Release (%) at 42°C in 100%
FCS
Zeta
potentia
l after
loading
(mV)
Before
loadin
g
After
loadin
g
Before
loading
After
loading
Before
loadin
g
After
loadin
g
5mi
n
1h 20se
c
1min 10mi
n
1h
1)
DPPC/DSPC/DSPE
-PEG 7/2.5/0.5
Citrate-Na
(pH 4.0)
84±2 85±1 0.03±0.
01
0.04±0.
02
0.15/1 0.167/
1
38±
5
49±
5
99±
1
99±1 98±2 90±
6
-6.7±0.3
2)
DPPC/DSPC/DSPE
-PEG 7/2.5/0.5
(NH4)2SO4
(pH 5.5)
83±1 82±1 0.04±0.
02
0.04±0.
02
0.15/1 0.158/
1
29±
4
43±
2
99±
1
99±1 99±1 92±
2
-7.7±0.2
3)
DPPC/DSPC/DSPE
-PEG 7/2.5/0.5
Oxalate-NH4
(pH 5.5)
86±1 84±2 0.03±0.
01
0.03±0.
01
0.15/1 0.143/
1
25±
3
41±
4
99±
1
99±1 96±1 91±
3
-7.2±0.5
4)
DPPC/DSPC/DSPE
-PEG 7/2.5/0.5
EDTA-NH4
(pH 5.5)
86±3 85±2 0.06±0.
03
0.07±0.
01
0.15/1 0.152/
1
14±
2
23±
2
99±
1
99±1 99±1 93±
3
-7.6±0.6
5) DPPC/DSPC/
Cholesterol/DSPE-
PEG 7/2/0.5/0.5
EDTA-NH4
(pH 5.5)
87±2 86±2 0.04±0.
03
0.05±0.
02
0.15/1 0.151/
1
16±
2
27±
1
71±
1
80±2 99±1 99±
1
-6.5±0.2
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6)
DPPC/DSPC/Paraff
in/DSPE-PEG
7/2/0.5/0.5
EDTA-NH4
(pH 5.5)
83±2 81±3 0.05±0.
02
0.04±0.
02
0.15/1 0.17/1 13±
1
28±
2
72±
2
84±1 99±1 99±
1
-6.8±0.6
7)
DPPC/DSPC/DSPE
-PEG 8/1.5/0.5
EDTA-NH4
(pH 5.5)
85±0 84±1 0.06±0.
02
0.07±0.
02
0.15/1 0.164/
1
19±
2
26±
1
87±
4
93±5 99±1 94±
1
-7.2±0.4
8)
DPPC/DSPC/DSPE
-PEG 6/3.5/0.5
EDTA-NH4
(pH 5.5)
87±2 86±2 0.06±0.
01
0.04±0.
02
0.15/1 0.147/
1
16±
0
21±
1
99±
1
97±1 92±1 90±
4
-7.2±0.6
9)
DPPC/DSPC/DSPE
-PEG 5/4.5/0.5
EDTA-NH4
(pH 5.5)
86±3 87±1 0.05±0.
02
0.06±0.
01
0.15/1 0.162/
1
14±
0
19±
2
66±
5
80±6 79±5 77±
3
-8.4±0.3
10)
DPPC/DSPC/DSPE
-PEG 6/3.5/0.5
EDTA-NH4
(pH 4.5)
88±2 88±1 0.05±0.
01
0.06±0.
01
0.15/1 0.139/
1
15±
1
21±
1
99±
1
97±2 94±2 89±
3
-8.0±0.2
11)
DPPC/DSPC/DSPE
-PEG 6/3.5/0.5
EDTA-NH4
(pH 6.5)
85±2 85±1 0.08+0.
01
0.07±0.
01
0.15/1 0.155/
1
13±
1
21±
2
99±
1
99±1 96±2 93±
1
-8.4±0.3
12)
DPPC/DSPC/DSPE
-PEG 6/3.5/0.5
EDTA-NH4
(pH 6.5)
131±4 130±5 0.07±0.
01
0.07±0.
02
0.15/1 0.172/
1
14±
2
20±
3
96±
1
91±2 83±5 91±
2
-8.5±0.6
13)
DPPC/DSPC/DSPE
EDTA-NH4 84±2 80±1 0.06±0.
01
0.05±0.
02
0.30/1 0.302/
1
13±
1
20±
2
99±
1
99±1 97±1 91±
3
-7.5±0.2
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-PEG 6/3.5/0.5 (pH 6.5)
14)
DPPC/DSPC/DSPE
-PEG 6/3.5/0.5
EDTA-NH4
(pH 6.5)
86±2 81±2 0.05±0.
02
0.04±0.
02
0.45/1 0.488/
1
15±
2
27±
1
99±
1
99±1 97±2 88±
3
-5.8±0.3
15) DSPC/DSPE-
PEG 9.5/0.5
EDTA-NH4
(pH 6.5)
87±3 85±2 0.07±0.
02
0.05±0.
02
0.30/1 0.289/
1
2±1 10±
3
1±1 3±1 11±5 17±
3
-7.3±0.6
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To investigate the effects of different DPPC percentages on IDA-TSL
stability, a series of IDA-TSL formulations were prepared by using 80%,
70%, 60% and 50% DPPC with matching percentage of DSPC and 5%
DSPE-PEG (formulation 7 = TSL80, formulation 4 = TSL70, formulation
8 = TSL60 and formulation 9 = TSL50 in Table 1). As seen in Figure 2B,
IDA-TSL exhibited a decline in leakage at 37°C from TSL80 of ~26%, to
TSL70 of ~23%, to TSL60 of ~21% and to TSL50 of ~19%. Besides, the
release rates of these four formulations at 42 °C were also different,
among which TSL80 showed maximum release after ~2 min, and TSL70
need approximately ~10 seconds, whereas TSL60 exhibited a complete
release within 1-2 seconds. By contrast, around 1-2 min of delay was
observed in TSL50 to reach the maximum release, which was ~80% of
IDA at that time point when exposed to 42°C. Based on these results, we
selected the IDA-TSL60 formulation (DPPC/DSPC/DSPE-PEG: 6/3.5/0.5)
for the following optimization.
Figure 2. The influence
of adding cholesterol or
paraffin (A) and
changing DPPC
percentage (B) in
liposome composition on
idarubicin (IDA) release
from 85 nm IDA-TSL at
37°C (blue) and 42°C
(black) in FCS for 1 h.
Loading buffer was
ammonium EDTA with
pH 5.5. (Three
independent tests were
performed. A
representative release
profile is shown.)
3.1.3. The influence of
internal EDTA pH on
IDA-TSL stability
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To access the effects of electrostatic attraction on IDA-TSL stability, we
prepared a series of internal pH of 4.5, 5.5 and 6.5 by adding ammonia to
EDTA solutions to load IDA, while an external pH of 8.5 (for pH 4.5/5.5
inside) or 9.5 (for pH 6.5 inside) was maintained, respectively
(formulation 8, 10, 11 in Table 1). Complete encapsulation was obtained
for these three formulations (Table 1). As shown in Figure 3, these
formulations had comparable stability, which exhibited a leakage of
~20% at 37°C after 1 h. Likewise, immediately maximum release at 42°C
was observed in all three formulations. By comparison, IDA-TSL with
pH 6.5 inside seemed to have 1-2% less leakage than the other two
formulations, therefore, ammonium EDTA solution with pH of 6.5
(external pH 9.5) was applied in subsequent formulations.
Figure 3. The influence of ammonium
EDTA pH on idarubicin (IDA) release
from 85 nm IDA-TSL at 37°C (blue)
and 42°C (black) in FCS for 1 h. IDA-
TSL was composed of
DPPC/DSPC/DSPE-PEG:6/3.5/0.5.
(Three independent tests were
performed. A representative release
profile is shown.)
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3.1.4. The influence of liposome sizes on IDA-TSL stability
Liposomes with different sizes exhibit various extents of curvature, which
can affect their contents release profiles [47,48]. Hence, we formulated
IDA-TSLs with diameters of ~85 nm and ~130 nm (formulation 11-12 in
Table 1). We observed that IDA-TSL of ~130 nm did not demonstrate
any improvement on stability (leakage of ~20%) at 37°C compared with
IDA-TSL ~85 nm (Figure 4A). Interestingly, at 42°C, large IDA-TSL
showed an immediate and maximum release followed by a sudden drop
down to ~90%; whereas we did not observe this with small sized IDA-
TSLs. The same trend was observed with IDA-TSL with a diameter of
~180 nm at 42°C, also showing a low leakage of ~20% at 37 °C (data not
shown). Therefore, we continued to use liposomes with a diameter of ~85
nm.
3.1.5. The influence of drug to lipid ratios on IDA-TSL stability
To evaluate the effects of drug/lipid ratios on IDA-TSL release, three
IDA-TSL formulations with drug to lipid molar ratios of 15%, 30% and
45% were prepared, respectively (formulation 11, 13-14 in Table 1). As
Figure 4B illustrates, increasing the drug/lipid ratio to 30% did not further
improve IDA retention in liposomes, presenting almost the same release
profiles as drug/lipid ratio of 15%, with leakage of ~20% at 37 °C and
ultrafast maximal release within 1-2 seconds at 42°C in 100% FCS. By
comparison, 45%-drug-loaded IDA-TSL was less stable by showing an
increased leakage of ~27% at 37°C for 1 h-incubation, although it
revealed a complete encapsulation of IDA (Table 1) and had an
immediate release at 42°C as well. Therefore, both drug/lipid ratios of
15% and 30% were determined to be suitable for optimized IDA-TSL
formulations.
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Figure 4. The influence of liposome size (A) and drug/lipid ratio (B) on
idarubicin (IDA) release from IDA-TSL at 37°C (blue) and 42°C (black)
in FCS for 1 h. IDA-TSL was composed of DPPC/DSPC/DSPE-
PEG:6/3.5/0.5, loaded by ammonium EDTA pH 6.5. (Three independent
tests were performed. A representative release profile is shown.)
3.1.6. The temperature-dependent release of IDA-TSLs
In the temperature-dependent release test, we compared IDA-TSL60 with
IDA-TSL70 and IDA-TSL50, at a molar drug-to-lipid ratio of 15% loaded
by EDTA with pH 6.5, from 30 °C to 45°C at an interval of 1°C. As
shown in Figure 5, all these three formulations displayed leakage
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beginning at 30-31°C followed by gradual increase until 38°C after 5 min
incubation in 100% FCS. However, IDA-TSL70 revealed a significant
release of ~60% at 39°C to almost complete release at 40°C; while IDA-
TSL60 exhibited a drug-release of only 35% at 40°C but a massive
release of ~75% at 41°C, following by reaching maximum IDA release at
42°C. As expected, the release of IDA-TSL50 was incomplete at 42°C
and reached its maximum at 44°C.
Figure 5. Temperature-dependent idarubicin (IDA) release from IDA-
TSL with decreasing percentage of DPPC (respectively 70, 60 or 50%)
during 5 min incubation in FCS at different temperatures. IDA-TSL70
(blue circle), IDA-TSL60 (black square) and IDA-TSL50 (red triangle).
N=3.
3.1.7. Cryo-TEM imaging
Figure 6 shows IDA-EDTA precipitates inside IDA-TSLs with drug/lipid
ratios of 30 mol% by cryo-TEM analysis. Less rounded liposomes were
observed after IDA loading. IDA-EDTA precipitates presented as
irregular appearance in the interior of TSLs.
42
Figure 6. Cryo-TEM image of idarubicin containing thermosensitive
liposomes (IDA-TSL) composed of DPPC/DSPC/DSPE-PEG (6/3.5/0.5)
with 30 mol% IDA loading by ammonium EDTA pH 6.5. Bar, 200 nm.
3.2. In vitro cytotoxicity of IDA-TSLs
IDA-TSL (DPPC/DSPC/DSPE-PEG: 6/3.5/0.5) with 30% of drug loading
formulation was used for the cytotoxicity tests in B16BL6, C26 and BLM
tumor cell lines. As illustrated in Figure 7, empty liposomes had
negligible cytotoxicity on all tested cell lines. Table 2 presents IC50 values
with/without mild hyperthermia that were calculated based on fitting
curves calculated with GraphPad Prism. The cytotoxicity of IDA-TSL
under HT (42°C) indicated nearly equivalent cytotoxicity to free IDA (at
37 and 42°C) in these three cell lines; while IDA-TSL at NT (37°C)
exhibited reduced cytotoxicity to cells leading to significantly increased
IC50 on B16BL6, C26 and BLM cell lines (Table 2, Figure 7). IDA-TSL
revealed an 11-fold decrease in IC50when combined with HT compared to
NT on C26 cells after 1 h treatment; while for B16BL6 and BLM cell
lines, IDA-TSL showed 6-fold and 3-fold reduction, respectively (Table 2,
Figure 7A-C). The same conclusion was evidenced by exposure of cell
lines to drugs for 3 days. (Table 2, Figure 7D-F).
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Table 2. IC50 (nM) of IDA-TSL in comparison with free IDA.
Co-incubation for 1 h Co-incubation for 3 days
B16BL6 C26 BLM B16BL6 C26 BLM
HT/NT HT/NT
IDA-TSL 8/46* 8/91* 14/44* 5/9* 0.37/4* 1/6*
IDA Free 7/7 7/7 10/15 4/4 0.31/0.34 1/1
*Nonparametric Mann–Whitney test, p value < 0.05. Data are represented
as Mean, N=3. HT: hyperthermia (42°C), NT: normothermia (37°C).
Figure 7. In vitro cytotoxicity of idarubicin containing thermosensitive
liposomes (IDA-TSL) on B16BL6 murine melanoma cell line (A,D), C26
murine carcinoma cell line (B,E) and BLM human melanoma cell line
(C,F) at 37°C and 42°C for 1 h or 3 days co-incubation. TSL empty
(diamond), IDA-TSL at 37°C (filled circle), IDA-TSL at 42°C (empty
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circle), free IDA at 37°C (filled square) and free IDA at 42°C (empty
square). Liposome composition was DPPC/DSPC/DSPE-PEG:6/3.5/0.5.
N=3.
3.4. Flow cytometry and in vitro imaging
Flow cytometry studies (Figure 8A,B), show overlapping peaks when
tumor cells were exposed to IDA-TSL 80, 70, 60, 50 (% DPPC), IDA-
TSL citrate (loaded by citrate buffer) and free IDA at 42°C, indicating
complete IDA release from TSL system. At 37°C, only minor differences
of leaked IDA were found from TSL 80 to 50, except that IDA-TSL
loaded with citrate buffer showed higher leakage, which was consistent
with above formulation optimization results. The peak fluorescence at
37°C, which represents IDA leaked from TSL 60 (at 20 µg/ml),
corresponds with the peak fluorescence observed with the same amount
of free IDA (at 5 µg/ml), confirming the stability of the TSL (data not
shown). Confocal imaging confirms that IDA-TSL released massive IDA
at 42°C and less IDA leaked at 37°C, resulting in less evident cellular
uptake (Figure 8C), though no obvious IDA leakage differences can be
seen among these TSLs. The confocal images show slightly reduced
idarubicin accumulation with TSL 50 compared to the others at 42°C.
Interestingly, more IDA accumulated in the cytoplasm (Figure 8C).
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Figure 8. A. In vitro activity of idarubicin (IDA) loaded in different
formulations was measured by flow cytometry at 37 and 42°C in BLM
cell. B. Based on A, peak fluorescence of each sample at 37 or 42°C was
calculated. C. Confocal imaging of cellular uptake of IDA released from
different TSL formulations at 37 and 42°C. Settings: IDA gain=500,
dimension=512 x 512. Bar applies for all images, 50 µm.
3.4. In vivo IDA-TSL release under local mild HT
In vivo IDA release from IDA-TSL was monitored by intravital
fluorescence microscopy using mice implanted with the murine B16BL6
melanoma in the dorsal skin flap window chamber (Figure 9 and
Supplementary video). As shown in Figure 9, at 37°C before applying HT,
there was no obvious leakage of IDA observed in the vessels after
injecting IDA-TSL at a dosage of 4 mg/kg (Figure 9A). IDA-TSL began
to release intravascularly when mild hyperthermia was started from 37°C
to 42°C which was reached within 4 min (Figure 9B,C). IDA release
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continued and extravasated towards the interstitial space, showing
massive release and penetration approximately within 15 min post-HT
(Figure 9D-F). Subsequently, released IDA in the interstitial space was
taken up by tumor cells. From 30 min post-HT, no apparent change on
IDA release and penetration can be seen. The IDA fluorescent signal in
vessels decreased as a consequence of wash-out by blood flow (Figure
9G,H). In agreement with the in vitro confocal images more IDA was
observed to accumulate in the cytoplasm; while nuclear accumulation was
less evident (see the white arrows in Figure 9I,J).
Figure 9. In vivo idarubicin (IDA) release from IDA-TSL in murine
B16BL6 melanoma at 37 °C (A) and mild hyperthermia for 1 h (B-H).
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Cellular uptake of IDA after treatment with mild hyperthermia (I,J). Bar,
200 µm (A-H), 100 µm (I,J).
3.5. Tumor growth control
In human BLM melanoma-bearing NMRI nu/nu mice a dose escalation
study was performed starting with 1, 1.5 and 2 mg/kg in combination with
HT. At 2 mg/kg foot swelling and weight loss were encountered which
were outside of the set ethical boundaries. Therefore, a single low dose of
1.5 mg/kg IDA-TSL, which was accompanied by transient limited weight
loss, was used for further experiments. Clearly, free IDA was not
sufficient to produce a tumor response at this dose. However, IDA-TSL at
a dose of 1.5 mg/kg with local mild HT induced significantly suppressed
tumor growth over a time course of at least 20 days compared to free
IDA and saline with mild HT after a single dose treatment (p<0.002 for
both). Moreover, the efficacy of IDA-TSL with HT was superior to Doxil,
even though the latter was used at a cumulative dose of 7.5 mg/kg
(p<0.005). Yet IDA-TSL with NT hardly produced tumor suppression
comparable to free IDA and saline with or without HT (Figure 10A). By
day 20, all mice treated with IDA-TSL plus HT survived (Figure 10B),
with an average tumor size below 400 mm3; while other groups of mice
had to be euthanized before day 20 due to large tumor volume. In IDA-
TSL plus HT group, 4 out of 6 mice had a complete abrogation of tumor
growth during 30 days (IDA-TSL HT vs Doxil, p<0.05). Mice presented
acceptable body weight loss, maximally 15% on day 8-9 after IDA-TSL
plus HT treatment, followed by gradual recovery (Figure 10C).
Figure 10. Tumor response in mice treated idarubicin containing
thermosensitive liposomes IDA-TSL (circle), free IDA (triangle) and
saline (square) in combination with local mild hyperthermia (HT, closed)
or normothermia (NT, open), Doxil was used as a standard clinic
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comparison (A). Comparison of mice survival rate (B, p<0.05 for IDA-
TSL HT compared to Doxil) and body weight after treatment (C). Data
are represented as mean±SEM, N=6.
4. Discussion
In this study we developed a novel, well-defined idarubicin
thermosensitive liposome formulation, which was prepared by applying
DPPC/DSPC/DSPE-PEG (6/3.5/0.5 mol%) and using the approach of
ammonium EDTA remote drug loading. Approximately 100% of
encapsulation efficiency is obtained. This IDA-TSL possesses an ultrafast,
triggered release of IDA by applying mild HT (42°C), while a low
leakage was observed at body temperature.
Classic liposomal remote loading approaches (such as sodium citrate and
ammonium sulfate gradients) induced higher leakage when used to load
the hydrophobic anthracycline idarubicin. Ammonium EDTA loading
approach, developed by Gubernator et al. [39], showed less IDA leakage
from liposomes due to the lower water-solubility of IDA-EDTA
precipitate compared to other IDA precipitates at pH 4.0-6.5, thus
promoting IDA retention inside thermosensitive liposomes.
Cholesterol and paraffin, the highly lipophilic small molecules cholesterol
and paraffin, were added in TSL formulation to increase the rigidity of
liposomal membrane [48,49], which we speculated may decrease leakage
of IDA-TSLs at 37°C. However, the leakage was not diminished but
slightly increased at 37°C and retarded release at 42°C, which are
probably due to the presence of cholesterol molecules that can increase
the liposomal membrane fluidity at temperature below Tm and decrease
the membrane fluidity above Tm [50]. Additionally, interaction between
IDA and cholesterol by forming complexes also possibly limits IDA
release at 42°C [40,51].
Changing the DPPC percentage of the liposomal composition affected
two features of IDA-TSL: IDA leakage at 37°C and IDA triggered-release
rate at 42°C. Increasing DPPC decreases Tm of liposome membranes. Li
et al. [41] demonstrated a reduced drug leakage with increasing Tm with
DXR-TSLs, which was consistent with the IDA-TSL results at 37°C
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shown here (Figure 2B). At 42°C, the release rate in our IDA-TSL
formulation is thought to be determined by the boundary density between
gel phase and liquid phase. Liposomes with different Tm cause different
densities of gel-liquid boundaries at a given temperature. TSL60 is
supposed to produce the highest gel-liquid boundary densities for IDA
efflux at 42°C, which exhibited the fastest release rate in the four
formulations. TSL70, due to a relatively low Tm, is believed to possess
excessive liquid phase in the membrane at 42°C, leading to relatively less
boundary density for drug release. From the temperature-release, TSL70
showed complete release at 41°C (Figure 5), suggesting that at 41°C the
optimal density of gel-liquid boundary for IDA ultrafast release is
achieved. Similarly, the trend can be explained in the same way for
TSL80 with a lower Tm. For the same reason, relatively slow release of
TSL50 is due to insufficient liquid phase to yield enough gel-liquid
boundaries at 42°C. Increasing lipophilic DSPC also explains the
incomplete IDA release at 42°C in TSL50, owing to the more
incorporation of IDA in bilayer. TSL50 showing almost 100% release
when temperature was raised to 45°C (see Figure 5), can be attributed to
further enhanced densities of gel-liquid boundary, which was also
confirmed by our previous work on DXR [41].
We suspected that IDA-TSL stability is proportional to the ability to form
IDA precipitate by EDTA anions. In other words, if more stages of
ionization of EDTA are generated by increasing internal liposomal pH
(EDTA pKa1=2.07, pKa2=2.75, pKa3=6.24, and pKa4=10.34), then EDTA
anions could produce stronger electrostatic forces to IDA cations, thereby
forming more stable IDA precipitate. However, we observed no obvious
improvement, which might be because the solubility of IDA-EDTA
precipitation was also increased by higher pH [39], thus “neutralizing” the
benefit of enhanced electrostatic force.
Many investigators pointed out that decreasing liposomal size increases
the membrane curvature and causes looser packing of bilayer, thus
leading to faster content release [47,48]. According to the molecular
dynamics simulation study on lipid bilayer, Tieleman et al. found that
lipids escaping from a monolayer (termed as hydrophobic defect) caused
lateral diffusion of lipids and membrane fusion, consequently leading to
thinning of the bilayer in defect regions [52]. Based on this, we believe
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that more lipid loss occurs in smaller liposome as a result of increased
curvature, thus resulting in stronger membrane fusion. We speculate these
thinning membranes in defect regions are beneficial to penetration of
hydrophilic molecules, which is also concluded by Hossann et al [47].
Hence, IDA-TSLs with various sizes exhibited more or less the same
leakage at 37 °C possibly because of the high hydrophobicity of IDA. It is
not clear why 130 nm-IDA-TSL demonstrated a little drop after
maximum release at 42°C, however, based on the conclusion of Tieleman
et al. [52], small liposomes exhibit more contracted acyl chains than the
large ones in defect regions (which are also the drug release regions). We
speculate that the released IDA is more prone to adsorb back to the
lipophilic acyl tails in the larger liposome bilayer, resulting in drop on
fluorescent density.
Most of the IDA-TSL formulations exhibited a property in common:
ultrafast release at 42°C. Though underlying reason is currently not clear,
the release profiles of IDA-TSLs are comparable to DXR-LTSL which
incorporates lysolipids. We speculate that IDA-TSL is likely to have
similar ultrafast release mechanism. It is believed that lysolipids,
surfactant-like lipids, can form nano pores (~10 nm [16]) at Tm allowing
rapid release [15,16,53,54]. The hydrophobic nature of IDA enhances
interaction with the liposomal membrane and as such may affect triggered
release. Gallois et al. found IDA was prone to form self-association of 2-
3 molecules in lipid bilayer [51]. According to the size measurement of
DXR molecule of ~2.5 nm [54], the IDA di-/trimers are therefore
considered as ~5-7.5 nm in size because of their similar structures. The
large vacancies left by released IDA di-/trimers will probably be used as
pores to facilitate the ultrafast and massive release of IDA from liposomal
interior. The grain boundaries as a result of lipid chain mismatches have a
pre-phase transition at <Tm [53,54], we believe the incorporation of IDA
in the membrane increases these boundary defects, possibly causing a
further pre-phase transition at these grain boundaries. Hence, an initial
release can be observed in all IDA-TSL formulations at 37°C. For the
same reason, the gradually growing leakage of IDA from ~31°C,
demonstrated by the temperature-dependent release assay (Figure 5), can
be explained by the pre-phase transition happening at these grain
boundaries as well. We hypothesize that the release of IDA from TSL at
37°C is a feature of hydrophobic IDA. Liposomes of a relative non-
51
thermosensitive nature (DSPC/DSPE-PEG:9.5/0.5, Table1 formulation 15
and Supplementary Figure 1), released around 10% after 1 h incubation in
FCS at 37 and around 20% at 42°C. we speculate that IDA associated
with the liposomal membrane is released instantly when exposed to full
FCS, while IDA contained as a crystal in the liposomal core is released at
transition temperature. Hydrophobic drugs tend to accumulate more in the
lipophilic membrane during drug loading process, this, at least in full FCS
environment, will give rise to a relatively higher release from liposomal
formulations, which is also seen with for instance vincristine [55].
As TSL have a higher propensity of instability preparation and storage
have a more profound impact on product quality. General precautions
which improve liposome stability are storage under nitrogen or inert gas
such as argon to prevent oxidation. Also antioxidants can be used for this.
Coating of liposomes with PEG or applying a charge can prevent
liposome aggregation and fusion. Addition of cholesterol may increase
stability but this will affect the thermosensitive nature of the particle
(such as the results in IDA-TSL). To stabilize TSL storage at 4°C is
recommended. We observed less than 1% release of IDA from TSL over
a 8-week period in HEPES buffer at 4°C.
Uptake of IDA by tumor cells was affected by DPPC content and loading
buffer used. Although most of the formulations showed fast to ultrafast
release at 42°C and comparable leakage at 37°C, cells accumulated less
idarubicin from IDA-TSL50 compared to others at 42°C (Figure 8C,
which is supported by the flow cytometry results (Figure 8A,B)).
However, when applied in vivo performance of TSL seem to be less
influenced by small differences in stability and release rate, as we
observed with doxorubicin-based TSL, which is most likely due to the
more complex nature of the in vivo setting. Increased stability and limited
release of content at 37°C reduces side-effects and improve efficacy.
Moreover, fast local triggered release and rapid cellular uptake augments
tumor response. Optimization of IDA-TSL will therefore improve
performance in vivo. Systemic leakage at 37°C of all formulations is
within a range which is not likely to cause a difference in tumor response,
although systemic toxicity may vary. Additionally, IDA is released
maximally and within a very short time frame from all formulations when
HT is applied. As IDA is released by HT this quick and high local levels
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can therefore be expected the drug needs to act also quickly on the cells.
We hypothesize that these particular drug kinetics may therefore be a
more dominant determinant in in vivo efficacy.
The in vitro studies (cytotoxicity, flow cytometry and confocal imaging)
display a more striking and significant reduction in activity of IDA-TSL
exposed to 37°C compared to 42°C. These findings suggest that IDA-TSL
releases less at body temperature, leading to reduced toxicity in absence
of mild HT. When mild HT induced complete drug release from IDA-
TSL, comparable chemotherapeutic efficacy was observed in vitro to free
IDA (Figure 7, Table 2). As expected, in vivo drug release was negligible
before mild HT. However, with increasing temperature to 42°C, IDA-
TSL showed a triggered, intravascular IDA release, followed by IDA
penetration toward interstitial space and tumor cell uptake (Figure 9).
Rapid and profound release in the heated region explains the strong tumor
response to IDA-TSL in combination with HT, while no objective tumor
response was observed when no HT was applied [Figure 10]. IDA-TSL
also performed better than a dosing schedule with Doxil, of which the
later inflicted only some tumor growth delay. This is most likely due to
the intrinsic higher stability of Doxil resulting in slow release of its
contents and therefore poor intratumoral concentrations of bioavailable
drug [10]. Albeit the reason of IDA accumulation in extra-nuclei instead
of intra-nuclei is not clear yet [Figure 8,9], the same observation was
confirmed by Ma et al [33]. The work of Zohreh et al. [56], who found
IDA had low binding affinity to chromatin, indicated that less aggregation
of IDA with chromatin occurs inside cells compared with DXR.
Therefore, we surmise the extra-nuclei accumulation of IDA can be
ascribed to its high hydrophobicity.
Conclusion
In this study we successfully developed a novel and well-designed
idarubicin temperature-sensitive liposome formulation, which
demonstrates low leakage at physiological temperature and ultrafast
triggered drug release under mild HT. The significant difference in in
vitro studies between IDA-TSL with or without mild HT and desirable in
vivo intravascular drug release by local mild HT explains the profound
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tumor response found in BLM tumor-bearing mice compared to the free
drug and Doxil treated mice. These results indicate the potential of IDA-
TSL for further development in combination with HT. Further
investigation is currently performed to unravel the underlying ultrafast
release mechanism at 42°C and on the optimal therapeutic efficacy of
IDA-TSL in different solid tumors.
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Supporting data
Supplementary Figure 1. The release profiles of idarubicin (IDA)
containing non-thermosensitive liposomal formulations at 37°C (blue)
and 42°C (black) in FCS for 1 h. IDA-NTSL 1 (left) was composed of
DSPC/DSPE-PEG: 9.5/0.5. IDA-NTSL 2 (right) was composed of
HSPC/Cholesterol/DSPE-PEG: 5.5/4/0.5. (Three independent tests were
performed. A representative release profile is shown.)
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Abstract
Thermosensitive liposomes (TSL) receive attention due to their rapid
externally controlled drug release at transition temperature in combination
with hyperthermia. This rapid release feature of TSL occurs when the
liposome membrane is going through a phase change which results in
numerous interfaces, at so-called crystal grain boundaries. Based on
experience with TSLs, our group found that thermosensitive liposomes
formulated by binary compositions of DPPC and DSPC at proper ratios
are able to exhibit rapid release without incorporation of release-
promoting components. The aim of this study was to understand the
mechanism of rapid release from bi-component DPPC-DSPC based TSL.
Based on the investigation of a series of TSLs formulated by different
DPPC-DSPC ratios, and through the analysis of binary-phase diagrams of
DPPC-DSPC TSLs, we conclude that inhomogeneous crystal grains are
formed in bi-component TSL membranes rather than mono-component,
thereby facilitating content release. The resulting inhomogeneous
membrane pattern is affected by DPPC/DSPC ratio, i.e. this determines
the number of interfaces between solid and liquid phases at transition
temperature, which can be diminished by addition of cholesterol. At
appropriate DPPC/DSPC ratio, substantive solid/liquid interfaces can be
generated not only between membrane domains but also between crystal
grains in each domain of the liposome membranes, therefore improving
content release from the TSL at transition temperatures.
Keywords:
Thermosensitive liposome, DPPC, DSPC, inhomogeneous crystal grain,
phase transition, release kinetics
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1. Introduction
Nanoparticle-mediated chemotherapy offers several advantages in tumor
treatment, including reduced side-effects, prolonged circulation time and
possibly improved intratumoral drug accumulation due to the enhanced
permeability and retention (EPR) effect [1]. Especially lipid-based
particles, liposomes, are successfully developed of which Doxil®/Caelyx®
is one of most well-known and widely used. However, application of
nanoparticles also introduces drawbacks, such as failure to adequately
penetrate tumors [2]. The EPR effect is influenced by tumor
microenvironment, tumor type and profile of nanoparticle, which all may
hinder an optimal therapeutic effect of most conventional, passively-
delivered liposomal formulations [3 ， 4]. Important, and the key
explanation for failure of Doxil® to surpass doxorubicin, is the slow drug
release from the liposome, which limits therapeutic efficacy in spite of
strikingly increased circulation time [5]. Hence, to obtain high local levels
of free and bioavailable drug actively triggered release of encapsulated
drug at the diseased site is a pursued possibility. One approach for local
delivery is to use thermosensitive liposomes (TSL) and local
hyperthermia (HT), in which the drug is rapid intravascularly released in
the heated area, subsequently followed by massive uptake by tumor cells
due to high concentration gradients.
The concept of thermosensitive liposomes was first introduced by Yatvin
et al.[6], reporting a TSL formed by 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) alone or with 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), which generates content release at a phase
transition temperature around 42°C. Nevertheless, these TSL relatively
slowly release their content limiting further application [7]. To enhance
release from TSL, Needham et al. improved TSL composition by
incorporating lysolipid (LPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy(PEG)-2000 (DSPE-PEG2000) in
DPPC-based formulations. These LPC-containing TSLs show over 80%
release in a matter of seconds at around 41°C, achieving a rapid release
profile necessary for intravascular delivery [8,9]. Currently, several
different thermosensitive liposomal formulations have been reported [10].
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The principle of TSL release is generally thought to result from phase
separation at Tm causing interfaces or gaps in the bilayer enabling content
release [10]. Ickenstein et al. proposed that lipids solidify into gel-phase
domains in the membrane during cooling, and boundaries appear at
adjacent domains due to spherical bending force [11]. Because of a high
degree of disordered lipid-arrangement in domain boundaries, these
regions possess lower melting points. This causes prior phase transition at
domain boundaries, thus generating interfaces between gel/liquid-
crystalline phases, which are in turn responsible for release of content
[11,12]. Surfactant lysolipids tend to migrate to phase interfaces and form
micelle-structures at phase transition, thus inducing nano-pores in
membranes, which can be stabilized by PEG-linked lipids. Together they
increase and enlarge the interfaces inflicting more rapid release [9,13].
Based on the same principle, Tagami et al. added Brij surfactants into
DPPC-based TSL, which exerts comparable fast release in response to
hyperthermia [14].
Most thermosensitive liposomes are formulated on the initially proposed
matrix composed of DPPC and DSPC phospholipids [15-18]. Especially,
in our group we have been working on DPPC-DSPC based
thermosensitive liposomes for years and developed several PEG-DSPE-
modified DPPC-DSPC based TSLs loaded with different drugs, showing
desired temperature response [19-22]. In the follow-up study, we
observed that TSLs formulated at proper DPPC/DSPC ratios exhibit rapid
release at transition temperatures. However, this fast release is likely not
explained by the defect mechanism of Ickenstein [11], and does not result
from the nano-pore effect seen with lysolipid-based TSL as proposed by
Needham et al [9]. We speculate that apart from boundaries between
individual domains as defective regions in membranes, other release
regions and factors exist that influence content release from DPPC-DSPC
based TSLs at transition temperatures. Therefore, in this study we
designed DPPC-DSPC based TSLs, investigated rapid release at certain
DPPC/DSPC ratios during phase transition, and elucidated the principle
to achieve an optimal heat-triggered release DPPC-DSPC based liposome
system.
2. Materials and methods
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2.1 Chemicals and agents
1,2-dipalmitoyl-sn-glycero-3-phosphcholine (DPPC), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG) were provided by Lipoid
(Ludwigshafen, Germany). Purified carboxyfluorescein (CF) was kindly
provided by Dr. Lars Lindner and colleagues. PD-10 columns were
obtained from GE Healthcare (UK). Cholesterol and other chemicals were
purchased from Sigma Aldrich unless otherwise specified.
2.2 Preparation of liposomes
TSLs were composed of DPPC/DSPC/DSPE-PEG in a molar ratio of
x/(100-x)/5 (x=100, 80, 60, 40, 20, 0) by using the thin lipid film
hydration method, followed by heated extrusion [19]. Briefly, 100 µmol
of lipids was dissolved in methanol/chloroform (1/9 v/v) mixed solvent
which was then evaporated at 40°C, followed by nitrogen flush for 30 min
to remove residual solvent. The resulting dried lipid film was hydrated
with CF (100 mM, pH 7.4) solutions at 60°C. Small unilamellar vesicles
were obtained by extrusion through Nuclepore® (Whatman Inc., USA)
filters with pore size of 100 nm on a Thermobarrel extruder at 65°C
(Northern Lipids, Canada). Unencapsulated CF was removed with a PD-
10 column. Diameter (Z-average) and polydispersity index (PDI) were
measured by using Zetasizer Nano-ZS (Malvern Instruments Ltd., UK).
2.3 Differential scanning calorimetry
Determination of TSL phase transition temperatures was done through
differential scanning calorimetry (DSC) (NETZSCH Scientific
Instruments Ltd DSC200F). Six DPPC-DSPC based formulations were
prepared as mentioned in 2.1 with or without CF loading. 30 mg of
liposome with/without encapsulated CF in fetal calf serum (FCS) or in
HEPES solution (pH 7.4), and the appropriate reference solution (HEPES
solution), were added to the sealed aluminum container. The phase
transition temperature range was measured over a temperature range of 30
to 70°C at an interval of 5 °C/min increase. High purity nitrogen was used
as carrier gas at rate of 10 ml/min.
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2.4 CF-loaded TSL time- and temperature-dependent release
20 μl of 1 mM [lipid] CF-TSL suspension was added to 2 ml 100% FCS
in a quartz cuvette at a series of determined temperature for 10 min. Real-
time release of CF was detected with a water bath combined
spectrofluorimetry (Ex. 493 nm/Em. 517 nm, Ex. slit 5 nm/Em. slit 5 nm)
(Hitachi F-4500 Fluorescence Spectrophotometer, Japan). The average
fluorescence intensity of the initial 5 seconds was recorded as I0 of CF-
TSL release, while fluorescence was measured as It at 10 min. After 10
min, detergent (10% Triton X-100) was used to disrupt all liposomes to
measure maximal CF fluorescence, which was recorded as Imax. Release
(%) = (It - I0)/(Imax - I0)× 100.
2.5 Thermokinetic release of CF-loaded TSL
Time-dependent CF release curves obtained from 2.4, were fitted using
three most common kinetic models (which are zero order, first order and
Higuchi equations, respectively, see below), to determine the best-fitting
profile of release kinetics and corresponding release rate [23].
Zero order: Mt= M0 + k0t
First order: In (1- Mt) = M0 - k1t
Higuchi: Mt = M0 + kht1/2
where Mt is the amount of content released at time t. M0 is the initial
amount of release at time =0. k0, k1 and kh represent the release rate
constant of zero-order, first-order and Higuchi, respectively. Here, Mt
represents the percentage CF released at time t, which was recorded based
on CF fluorescence intensity.
2.6 Activation energy of CF release
Activation energy (Ea) of CF release from TSLs composed of different
DPPC and DSPC ratios can be calculated by using Arrhenius indefinite
integral equation:
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In k = -(Ea/R)*(1/T) + B
where k is CF release rate constant which can be obtained based on
methods mentioned in 2.5, B is a constant, R is the universal gas constant,
and T is expressed as thermodynamic temperature in kelvin.
2.7 Statistical analysis
Data were analyzed using Mann-Whitney U test or Kruskal-Wallis test
followed by Dunn test when appropriate. P-values below 0.05 were
considered significant.
3. Results
3.1 Differential scanning calorimetry
DPPC-DSPC based liposome formulations with or without encapsulated
CF were prepared with diameters between 110 and 120 nm and PDI
below 0.1 (Table 1). Liposomes were measured in FCS and HEPES
buffer solution by DSC, respectively. As seen in Fig. 1, Tm increased
with increasing DSPC content in the liposomal composition. Only one
phase transition peak was observed with each formulation and the Tm
was between those for pure DPPC and pure DSPC liposomes. These data
suggest that a molecular dispersion system (solid solution) was achieved
in DPPC-DSPC mixed lipid membranes. By comparison, when CF was
encapsulated, liposomal Tm did not show significant changes in HEPES
or FCS solution (Table 2).
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Table 1 Characterization parameters of DPPC-DSPC based CF TSLs.
Mean±SD, N≥3.
TSL composition
(mole)
Particle size (nm)
(Z-average) #
Polydispersity index
DPPC/ DSPE-PEG
100/5
(TSL 100)
117±5 0.07±0.01
DPPC/DSPC/DSPE-
PEG 80/20/5
(TSL 80)
119±3 0.05±0.03
DPPC/DSPC/DSPE-
PEG 60/40/5
(TSL 60)
113±2 0.07±0.02
DPPC/DSPC/DSPE-
PEG 40/60/5
(TSL 40)
120±4 0.04±0.01
DPPC/DSPC/DSPE-
PEG 20/80/5
(TSL 20)
115±3 0.05±0.02
DSPC/DSPE-PEG
100/5
(TSL 0)
119±6 0.06±0.02
# The Z-average of particle was reported by Zetasizer, which was
measured based on Comulant model.
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Table 2.DPPC-DSPC liposome phase transition temperature.
Lipid
composition
Internal
solution
External
solution
Phase
transition
temperature
Initial
temperature
of phase
transition
Terminal
temperature
of phase
transition
100% DPPC
(TSL 100)
HEPES HEPES 41.7 38.7 45.4
CF HEPES 41.0 40.4 43.2
FCS 41.1 40.4 43.4
80% DPPC
(TSL 80)
HEPES HEPES 43.9 41.1 47.0
CF HEPES 43.7 42.5 45.9
FCS 43.6 42.4 45.5
60% DPPC
(TSL 60)
HEPES HEPES 46.8 43.3 49.7
CF HEPES 46.4 44.5 48.6
FCS 46.4 44.5 48.7
40%DPPC
(TSL 40)
HEPES HEPES 49.4 46.5 52.3
CF HEPES 49.5 47.1 51.4
FCS 49.5 47.2 51.5
20% DPPC
(TSL 20)
HEPES HEPES 52.1 50.0 54.3
CF HEPES 52.0 50.2 54.4
FCS 51.9 50.3 53.9
0% DPPC
(TSL 0)
HEPES HEPES 54.6 52.8 57.1
CF HEPES 54.2 53.6 55.9
FCS 54.3 53.6 56.3
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Figure 1. DSC scans of empty liposome in HEPES (A), CF-loaded
liposomes in HEPES (B) or in FCS (C). TSL100-0 represent liposomes
formulated at (100/5:DPPC/PEG), (80/20/5:DPPC/DSPC/PEG),
(60/40/5:DPPC/DSPC/PEG), (40/60/5:DPPC/DSPC/PEG),
(20/80/5:DPPC/DSPC/PEG) and (100/5:DSPC/PEG), respectively.
3.2 Pseudo-binary phase diagram of DPPC-DSPC liposomes
Based on initial and terminal temperatures of phase transition measured
by DSC in Table 2, a pseudo-binary phase diagram of DPPC-DSPC
liposome is plotted (Fig. 2.). Lines in green are the liquidus and solidus
curves of CF-TSL measured in FCS, and lines in red are for samples
measured in HEPES. Almost overlapping curves were observed in both
media.
Figure 2. Pseudo-binary phase diagram of CF TSL plotted from the
initiation and completion temperatures deducted from DCS measurements
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in HEPES buffer (red line) and FCS (green line). Samples were
formulated as DPPC-DSPC liposomes with CF loading for measurement.
3.3 Time-dependent release of CF from DPPC-DSPC formulations in
FCS
DPPC-DSPC based liposome formulations with encapsulated CF were
tested for triggered release in FCS at different temperatures for 600
seconds, respectively. Each CF release curve (Fig. 3) was fitted by the
three release kinetic equations described in 2.5 separately to obtain the
best release equation match for each formulation based on the
determination coefficient R2 (Table 3). A better coefficient of
determination was obtained with the Higuchi release model when 40% or
more DPPC was present in the liposomal composition. While with DPPC
content equal to or lower than 20%, First order kinetics is more
approprate to describe CF release profiles. However, the differences
between these these three fitting models are minor.
Figure 3. CF time/temperature-dependent release in FCS from TSL100,
TSL80, TSL60, TSL40, TSL20 and TSL0. 100 – 0 indicates the
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percentage of DPPC. Mean of at least three independent measurements is
depicted.
Table 3. Kinetic profile of CF release from DPPC-DSPC based liposomal
formulations.
Determination coefficient R2
TSL100 TSL80 TSL60 TSL40 TSL20 TSL0
Zero
order
0.92797 0.91903 0.85759 0.88797 0.92630 0.94131
First
order
0.91137 0.92038 0.89323 0.91025 0.93410 0.94322
Higuchi 0.93806 0.95473 0.91194 0.95473 0.92467 0.89401
Determination coefficient was determined by curve fitting of at least 3
independent experiments per formulation. Mean is depicted.
Table 4 CF release rate constants at Tm of DPPC-DSPC based liposomal
formulations. Mean±SD.
TSL100 TSL80 TSL60 TSL40 TSL20 TSL0
#kTm
(10-4)
130±1 s-
1/2
290±104
s-1/2
580±139
s-1/2
640±193
s-1/2
270±48
s-1
140±75
s-1
# Based on determination coefficient shown in Table 3, the release rate
constants k were calculated by the most fit release equation at transition
temperatures of each formulation (Higuchi: TSL100-40; First order: TSL20-0)
and presented as 10-4 s-1/2 or 10-4 s-1. The first 20 seconds of measurement at Tm
were used for calculation of k [16].
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3.4 Temperature-dependent release of CF from DPPC-DSPC
formulations in FCS
Temperature-dependent release of the six DPPC-DSPC based liposome
formulations were compared at appropriate temperature ranges (Fig. 4A).
It was observed that with increasing temperature, regardless of DPPC-
DSPC composition, CF release from TSLs gradually increased until
reaching the maximum release temperature (Tm), and was then followed
by a rapid decrease as the temperature increased further. Additionally, the
maximum CF release at Tm from TSLs showed a significant
improvement with lower DPPC content; the highest release reached
73±4% from TSL20, while only 42±6% release was observed from
TSL80 at their Tm, respectively. Liposomes composed of pure DSPC or
DPPC showed however a reduced release of CF compared with other
binary-component liposomes during phase transition (Fig. 4A). Based on
calculations with the proper fitting release equations, CF release rate
constants of each formulation were computed at Tm, respectively (Table
4). As seen, kTm shows similar trend with the change of the amount of
DSPC in TSL.
A CF-release pseudo-binary phase diagram of DPPC-DSPC based TSLs
was plotted based on measured temperature release ranges shown in Fig
4B, which demonstrates similar profiles with DSC based phase diagram.
Figure 4. A: Temperature-dependent CF release from DPPC-DSPC based
liposomes in FCS. Mean±SEM are shown of at least 3 independent
experiments. B: Pseudo-binary phase diagram of CF TSL plotted on the
basis of CF release, in which release-starting temperature was recorded as
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onset of Tm and release cease-decrease temperature as the end of Tm.
*Kruskal-Wallis test followed by Dunn test, p value<0.05.
3.5 Activation energy of CF release from DPPC-DSPC formulated TSLs
Based on CF release data in Fig 4 and the Arrhenius equation, the
activation energy of CF release from these different liposomal
formulations was calculated (Table 4, Fig. 5). Both TSL 60 and 40
showed significantly lower activation energy for CF release, while the
other formulations exhibited higher activation energy, especially in
liposomes formulated by pure DPPC or DSPC lipids, suggesting that the
obstruction for CF release was minimal when these binary component
liposomes have a DPPC content between 40% and 60%.
Figure 5. Activation energy of CF release from liposomes composed of
various amount of DPPC-DSPC. *Kruskal-Wallis test followed by Dunn
test, p value<0.05; ns, not significant at the 0.05 probability level.
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3.6 The influences of PEG incorporation and PEG content on CF-TSL
release
Previously we demonstrated that incorporation of more PEG-DSPE
causes a higher CF leakage at phase transition [19]. We observed that 5
mol% PEG lipid in a standard formulation with DPPC-DSPC is enough to
generate content release from TSLs. In order to investigate the effect of
pure DPPC-DSPC TSLs composition on CF release we formulated
liposomes with a minimal amount of PEG. To avoid aggregation of the
nanoparticles 0.5 mol% PEG-DSPE is needed, which was added to all
formulations. An obvious decreased of CF release was observed from all
TSLs after reducing PEG lipid to 0.5 mol% compared to the original
formulations containing 5 mol% PEG (Fig. 6). A comparable trend was
observed concerning CF release at Tm which gradually increased from
TSL100 (7±3% vs 42±6% at high PEG formulation; nonparametric
Mann-Whitney test p=0.029) to TSL20 (46±6% vs 73±4%; p=0.016)
when minimal PEG was applied. Interestingly, unlike other TSL
formulations CF release from TSL0 seemed not to be influenced by PEG
content, showing 40±4% and 49±10% (p=0.114) release at high and low
PEG formulations, respectively.
Figure 6. Effect of PEG amount (5 mol% (open symbol) and 0.5 mol%
(closed symbol)) on temperature-dependent CF release from DPPC-DSPC
based liposomes in FCS. Mean±SEM are shown of 3 or more independent
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experiments. *Nonparametric Mann-Whitney test, p value<0.05; ns, not
significant at the 0.05 probability level.
3.7 The influences of cholesterol amount on CF-TSL release
Cholesterol is commonly used in many liposomal formulations, which
may however affect release kinetics profile of thermosensitive liposomes.
Based on the Doxil-like formulation, we investigated CF release from
TSLs composed of DSPC and 40, 20 and 10 mol% cholesterol. DSC
measurements (Fig 7A) of these TSLs displayed a gradually widened and
slightly declined phase transition temperature when increasing cholesterol
from 10 mol% to 20 mol% in comparison with no cholesterol contained
TSL. However, no phase transition can be detected when 40 mol%
cholesterol was applied. Temperature-dependent release assays confirmed
these observations with absent CF release at 40 mol% cholesterol, while
approximate 20% CF release was observed in formulations containing 10
and 20 mol% cholesterol formulations, both of which showed dramatic
release decrease compared to the original formulation.
Figure 7. DSC scans (A) and temperature-dependent release (B) of
liposomes composed of 40, 20, 10 and 0 mol% cholesterol and DSPC.
Results of 3 independent experiments are shown Mean±SEM.
4. Discussion
Here we demonstrate that bi-component DPPC-DSPC based TSLs have
an optimal lipid ratio at which release rate at transition temperature is
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maximal. We observe that with the increase of the amount of DSPC,
release rates increase as well (rTm in Table 5), and at an appropriate DPPC
and DSPC ratio bi-component TSLs release significantly faster than
mono-component liposomes at transition temperatures.
It is generally believed that thermosensitive liposomes exhibit the highest
permeability when reaching their Tm, which causes maximum interfaces
between solid and liquid phases in membranes, therefore leading to
massive release of content [10]. Besides, temperature may be positively
correlated to release rate [24] as the maximum release rates of these 6
formulations were measured at different and also increasingly higher
transition temperatures. In order to elucidate DPPC-DSPC based TSL
release kinetics, based on the general rules of diffusion release, namely
Fick’s first law, CF release rate can be given by:
r = -D*A* dC/dx =-K * T * A* dC/dx
where D represents diffusion coefficient and is proportional to
temperature, which can be presented as the product of temperature T and
constant K in this case. A is the diffusion area of release, and dC/dx is CF
concentration gradient inside and outside of the liposomal membrane,
which is the same in all TSL formulations. Herein both temperature and
the release area in membrane affect CF release rates. The interfaces
between solid and liquid phases in membrane of each formulation,
namely release areas, reach maximum at their respective Tm. When we
compare the TSL release rates using the experimental data measured at
the same temperature most of these TSL are not in the maximum solid-
liquid interface density. In order to compare their maximum release rates
and eliminate the temperature factor we used the definite integral form of
the Arrhenius equation (see below) to calculate the theoretical release
rates. To do so we chose a given and same temperature for all TSL
formulations but maintained the maximum release areas for each TSL
formulation. Thus their solid-liquid interfaces are remained as maximum
as are at their respective Tm, but the temperature is unified at in this case
at 42°C to calculate the theoretical release rates of each formulation
(Table 5).
In(kTm/k42) = In(rTm/r42) = Ea*(Tmax – T42)/(R*Tmax*T42)
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where rTm is the CF release rate measured at Tm of each TSL formulation,
which was obtained from the results in 3.3. Ea is the activation energy of
CF release, R is the universal gas constant, and T is expressed as
thermodynamic temperature in kelvin.
Table 5 CF release from different DPPC-DSPC based liposomes.
TSL 100 TSL 80 TSL 60 TSL 40 TSL 20 TSL 0
rTm
(%/min)
9.9±1.3 20.4±3.2 38.6±14.4 51.3±16.9 65.3±6.
9
45.1±12.2
Tmax (°C) 40 42 44 47 50 53
Ea (J/mol) 14029 11447 10118 9866 14621 18503
r42 (%/min) 10.3±1.3 20.4±3.2 37.7±14.1 48.4±16.1 56.9±6.
0
35.5±9.6
rTm (%/min): the experimentally measured CF release percentage in 1 min at
maximum release temperature.
Tmax: temperature of maximum CF release.
Ea: CF release activation energy in average.
r42 (%/min): the theoretically calculated CF release percentage for 1 min at 42°C
based on Arrhenius equation.
Mean±SD, N≥3
Release rates (r42) in Table 5 show the same trend of faster CF release
rates with increasing amount of DSPC in liposomes from TSL 100 to 20
but with a drop in TSL 0, implying temperature is not the main driving
force that varies CF maximum-release-rates among these TSLs. We
postulate that other factors intrinsic to the TSL formulation and used
components determine release kinetics.
As seen in Fick diffusion equation, the increase of DSPC in TSL may
increase the release area, thus leading to higher release. Hence, we
hypothesize that the amount of interfaces in the liposomal membrane
varies as a consequence of DPPC/DSPC ratios. The underlying
mechanism we propose is that optimizing the amount of DSPC generates
79
more solid-liquid interfaces in the membrane, increasing the release areas,
thus improving CF release rate at phase transition.
Binary phase diagrams can be used to illustrate the explanation of
increased release areas in DPPC-DSPC based TSLs (Fig 2 and 4B).
Unlike theoretical prediction, the experimental phase diagram did not
exhibit “closed” curves in TSL 100 and 0 liposomes, which is because
this is not pure bi-component system in literally. Presence of PEG lipid
and interaction with serum factors as well can influence phase transition
temperature of TSL 100 and 0, resulting in the deviation from the theory
[25]. Figure 2, was drawn on the basis of data measured by DSC, which
reflects the macro thermodynamic behavior of lipid membrane at
milligram scale. While Figure 4B was plotted based on the amount of CF
molecules released through the lipid membrane during phase transition,
reflecting the detection of mesoscopic behavior at nanogram scale.
Apparently, the latter is more sensitive as well as closer to reality when
tracking lipid membrane phase transition, which is able to indicate the
phase changes in lipid membrane earlier. Therefore, it is reasonable and
reliable to illustrate liposomal thermostability on the basis of the extent of
content release.
According to Figure 4B, the molar ratios of gel and liquid phase in
liposomal membranes at respective transition temperatures can be
calculated by Lever Rule (Fig. 8 and Table 6).
Lever Rule: ns(quantity of solids) * Ls(distance to solidus or to Y axis) = nl(quantity of liquid) *
Ll(distance to liquidus or to Y axis)
It was found that in TSL 60, 40 and 20 at Tm, which showed massive
release, the lipid membranes were composed of nearly equal amount of
gel phase and liquid crystalline phase, which may generate the maximum
solid/liquid interfaces in the membranes for content release. However,
around two third of the lipid membrane was in liquid crystalline state in
TSL 80 at Tm, thus inducing less interfaces between solid and liquid
phases, and hence diminishing CF release.
80
Table 6 The ratios of solid and liquid phase in liposomal membranes at
maximum CF release temperature of different DPPC-DSPC based
liposomes.
TSL 100 TSL 80 TSL 60 TSL 40 TSL 20 TSL 0
Tmax (°C) 40 42 44 47 50 53
n(s):n(l) (mol/mol) - 0.44 1.00 0.94 1.00 -
Figure 8. Pseudo-binary phase diagram modified from Fig 4B. A, B, C
and D represent the maximum release temperatures of respective CF-
TSLs and their distances to solidus and liquidus (along the drawn solid
red line) were used to calculate solid/liquid phase ratios at Tm. For TSL
20, Ls is distance from D to left Y axis; from A to right Y axis is Ll for
TSL 80.
Binary-component systems are inhomogeneous during crystal nuclei
formation and growth. Based on the above depicted DPPC-DSPC pseudo-
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binary phase diagram (Fig. 8), the composition of crystal grains is
constantly changing when cooling down from liquid crystalline phase to
gel phase. Crystal nuclei are initially formed by pure DSPC or with a little
DPPC during cooling, and DPPC increasingly accumulates at the growing
grains due to its lower melt point. Meanwhile solidified DSPC gradually
decreases with temperature decline. For example TSL 60 in Fig. 8, when
temperature declines to point E (48°C), numerous crystal nuclei are
formed as solid solution which is composed of 4.3% DPPC and 95.7%
DSPC. Growing crystal grains are subsequently formed by continuous
accumulation of solidified lipids to the crystal nuclei with further cooling
down, of which the percentage of DPPC is gradually increased with the
line F (48°C, 4.3% DPPC) to G (39°C, 60% DPPC). These crystal grains
stop growing when touching their adjacent grains. Therefore, the content
of DSPC in a crystal grain is decreases from crystal nucleus to outward
region, while the content of DPPC keeps increasing. Inhomogeneous,
multilayer structured crystal grains are largely formed in bi-component
membranes in this way, with gradually lowered melting points from the
core to the outer layers of each crystal grain.
Hence, according to analysis of the binary phase diagram we propose that
a DPPC-DSPC based bi-components liposomal membrane is composed of
a large amount of these inhomogeneous, nano-sized crystal grains (Fig. 9).
The contact regions of these crystal grains, namely the outmost layers of
crystal grains, form the crystal grain boundaries (green stripe in Fig. 9)
and, are rich in DPPC, thus leading to a lower melting point in these
regions compared with inner layers of crystal grains which are rich in
DSPC. Consequently, a priori phase transition occurs at these boundary
regions at transition temperature when heating up, which generates these
crystal grains outmost layers to melt but inner layers stay solid, thus
forming solid-liquid interfaces which allow content release in bi-
component TSLs. However, in mono-component liposomes homogeneous
crystal grains are formed in membranes, with a homogeneous melting
point from nucleus to outer region (Fig. 9). Thus, no solid-liquid
interfaces are formed between crystal grains of mono-component
membrane at transition temperature.
Next to the crystal grain formation, membrane defects (black stripes in
Fig. 9) are formed between membrane domains due to the curved
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spherical liposome surface [12]. Highly disordered arrangement of lipid
molecules occurs because of different lattice orientation [11], resulting in
a lower melting point in these defect regions. Hence priori phase
transition takes place in these regions in both bi- and mono-component
TSLs at transition temperature, forming interfaces between solid and
liquid phases for content release (Fig. 9). We argue that melting not only
happens at defect regions but also at numerous crystal grain boundaries
during phase transition. Thus bi-component membranes generate
significantly increased solid-liquid interfaces than mono-component
membranes, which only melt at defect regions at Tm (Fig. 9 middle row),
this results in faster and more content release in bi-component TSLs.
When heating above Tm, the whole liposome membrane is in a liquid
phase which takes away the solid-liquid interfaces, thus evidently
decreasing release as we observed in both bi- and mono-component TSLs
(Fig. 9 top row).
Figure 9. Crystal grains in bi-component liposomal membranes are
formed as inhomogeneous microstructures with lower melting point in the
outer layer, while mono-component crystal grains in a homogenous (i.e.
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mono-component) structure have the same melting point across the grains.
In membrane defect regions the melting point is also lower. At transition
temperatures, both grain boundary (green stripe) and defect (black stripe)
regions melt (pink) in bi-component TSLs, whereas only membrane
defect regions melt in mono-component TSLs at transition temperatures,
thus creating less gel/liquid interfaces for content release in TSL 100 and
0. When above transition temperatures, all TSLs are in pure liquid phase,
thus no interfaces for release are present. The transmission electron
microscopy graph of lipid membrane is cited from paper of Landon et al
[26] and authorized by the publisher.
In bi-component liposomes, however, maximum release varies
significantly between TSL 60, 40 and 20. Table 5 shows almost the same
solid-liquid phase ratios between these TSL 60, 40 and 20 at their
maximum release temperatures, but that does not imply that the amount
of interfaces between gel and liquid crystalline phases are the same. One
possible explanation could be that more crystal grains are formed when
liposomal membranes containing more DSPC, which hence generates
more solid-liquid boundaries at transition temperatures. Another
possibility is that due to the longer chain length and higher rigidity of
DSPC compared to DPPC molecules, more membrane defects are
generated in liposomal membranes containing more DSPC as a
consequence of higher curvature stress (Fig. 9 TSL 0). We indeed
observed that when the size is increased (Supplementary Fig.1,
Supplementary Tab. 1), lack of curvature stress in the lipid membrane
caused dramatically reduced release, especially in mono-component TSLs
which showed comparable extend of CF leakage (Supplementary Fig. 1
TSL 100 vs TSL 0); while bi-component TSL still demonstrated, but
reduced, heat-triggered release (Supplementary Fig. 1 TSL 60).
According to the phase diagram in Figure 8, the gel phase occupies 60%
of the membrane in TSL 20 when cooling down to point H (calculated by
Lever Rule). In addition, more than half of the membrane in TSL 20 is
solidified and formed by pure DSPC lipids at point H, thus creating a pure
DSPC-based continuous phase in membrane. While during cooling of
TSL 40 and 60, the continuous phases are solid solution composed of
DSPC and DPPC rather than pure DSPC. Continuous phases formed by
pure DSPC structurally differ from those formed by DPPC/DSPC solid
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solution. This may be another reason why TSL 20 and 0, with pure DSPC
as continuous phase in membranes, showed higher release than TSL 60,
40 and 100.
The activation energy of CF release (Fig. 5) gradually decreased from
TSL 100 to 40, which is due to the increased number of interfaces in
membranes that facilitate CF release. It requires high activation energy to
release CF from TSL 20 and 0, which can be attributed to the enhanced
hydrophobicity and thickness of the membrane as a consequence of
continuous phases composed of pure DSPC lipid in TSL 20 and 0, thus
needing high activation energy for CF release. However, it seems that
release from areas with enhanced leakiness, as results of bending defects
in membranes, supersedes the release obstruction resulting from high
activation energy. Therefore TSL 20 and 0 still showed fast CF release.
Komatsu et al. demonstrated that content release from a liposomal
aqueous core follows first order kinetics [27]. However, based on the
determination coefficient R2 (Table 3) resulted from fitting by three
kinetic equations in 2.5, we found that CF release better correlates with
the Higuchi model when liposome contained DPPC more than or equal to
40%. While it is proper described by the first-order release model when
more than 80% of the liposomal membrane is made up by DSPC. The
Higuchi model describes pore-based release models [28], which suggests
that especially TSL 80-40 are likely to present a pore-like release profile
during phase transition. These nano-scale pores result from the large
amount of solid-liquid interfaces in bi-component membranes. While for
TSL 20 and 0, due to the increase of long chain DSPC lipids in TSL the
membranes become thicker, leading to increased diffusion path length fro
CF in membrane, thus displaying first-order release pattern [28].
Importantly, in this study the fitting differences of these TSL release
profiles are not significant.
Taken together we conclude that interfaces between gel and liquid
crystalline phases are crucial for massive release of content at Tm.
Moreover, while typically liposomes are coated with PEG to prolong
circulation time, PEG facilitates rapid release kinetics as well. PEG lipids
tend to accumulate at interface areas due to their surface activity,
consequently stabilizing these interfaces to release CF [9]. Therefore,
when liposomes contain a low content of PEG lipids dramatically
85
diminished CF release was observed (Fig. 6). The lack of such an effect in
TSL 0 may be because the resulting interfaces in TSL 0 are more rigid
due to pure DSPC composition, thereby more stable interfaces are
generated in TSL 0 membranes enabling CF release even without help of
PEG. Additionally, PEG lipid (DSPE-PEG) has the same lipid moiety as
DSPC rather than DPPC, which could also explain the significant
decreased release in TSL 100 containing lower PEG lipids. Cholesterol is
applied to improve the stability of liposomal membranes, but it also
maintains a certain degree of fluidity of the membrane above as well as
below Tm [29]. Through this action cholesterol passivates the response of
TSL membrane to transition temperature by inserting between lipid
molecules which affects inter-molecular ordered arrangement of
phospholipids in the membrane [23,29]. As a result, we think, cholesterol
molecules obscure membrane defects and boundaries, leading to less or
no interfaces during phase transition. In addition, incorporation of
cholesterol increases the membrane lipophilicity and therefore barrier
function to hydrophilic compounds which likely explains the remarkable
decrease of CF release and declined thermosensitivity as observed in
cholesterol containing liposomes (Fig. 7).
Considering the applicable hyperthermia range in the clinic (40-43°C), a
DPPC content has to be selected which balances instability with rapid
release. TSLs with a DPPC content above 80% are prone to leak at
around physiological temperature because the membrane already goes
through phase transition at 37°C (Fig 8). The onset of phase transition of
liposomes with a DPPC content of 40% or lower on the other hand, starts
at 41°C, with only a minor fraction of the lipids convert to a liquid state.
Based on Level Rule, the percentage of liquid crystalline phase in the
membrane at this state is still low (~17%) even at 43°C, thus generating
lesser interfaces for release. Therefore, in DPPC-DSPC based
thermosensitive liposomes the amount of DPPC should be above 40% and
not beyond 80% for a fast triggered drug release at a preferred
hyperthermia temperature.
Conclusion
Thermosensitive liposomes are promising delivery systems for solid
tumor treatment combined with local hyperthermia. It is crucial that TSLs
display rapid content release when exposed to the right temperature,
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generating a steep drug gradient which benefits subsequent tumor uptake.
The present work, based on the analysis of phase equilibrium, illustrates
that inhomogeneous crystal grains consisting membranes form in DPPC-
DSPC bi-component TSLs. These inhomogeneous microstructurally
organized membranes offer numerous solid-liquid phase interfaces,
namely nano-scale gaps, at transition temperature at crystal grain
boundaries and defect regions, enabling rapid release. These induced
nano-scale gaps in liposome membranes are adjustable in quantity by
changing DPPC and DSPC ratios, thus presenting different release
kinetics, which can be used to further develop TSLs for wider application
in the clinic.
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Supporting data
Supplementary Figure 1. Effect of liposomal diameter on CF release
from mono-component or bi-component TSLs in FCS. Mean±SEM are
shown of 3 independent experiments.
Supplementary Table 1 Charaterization of CF TSLs of large diameter.
Mean±SD, N=3.
Liposome Z-average (nm) Polydispersity
TSL 100 170±7 0.05±0.02
TSL 0 177±4 0.06±0.02
TSL 60 184±7 0.05±0.03
88
References:
[1] Y. Matsumura, H. Maeda, A new concept for macromolecular
therapeutics in cancer chemotherapy; mechanism of tumoritropic
accumulation of proteins and the antitumor agent SMANCS, Cancer Res.
46 (1986) 6387-6392.
[2] X.L. Cun, J.T. Chen, S.B. Ruan, L. Zhang, J. Wan, Q. He, H.L. Gao,
A novel strategy through combining iRGD peptide with tumor-
microenvironment-responsive and multistage nanoparticles for deep
tumor penetration, ACS Appl. Mater. Interfaces 7 (2015) 27458-27466.
[3] H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami,M.
Kimura, Y. Terada, M.R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama,
K. Kataoka, Accumulation of sub-100 nm polymeric micelles in poorly
permeable tumours depends on size, Nature nanotechnology 6 (2001)
815-823.
[4] S.K. Hobbs, W.L. Monsky, F.Yuan, W.G. Roberts, L. Griffith, V.P.
Torchilin, R.K. Jain, Regulation of transport pathways in tumor vessels:
role of tumor type and microenvironment, Proc. Natl. Acad. Sci. 95 (1998)
4607-4612.
[5] A.L.B. Seynhaeve, S. Hoving, D. Schipper, C.E. Vermeulen, G. aan
de Wiel-Ambagtsheer, S.T. van Tiel, A.M.M. Eggermont, T.L.M. ten
Hagen, Tumor necrosis factor α mediates homogeneous distribution of
liposomes in murine melanoma that contributes to better tumor response,
Cancer Res. 67 (2007) 9455-9462.
[6] M.B. Yatvin, J. N. Weinstein, W. H. Dennis, R. Blumenthal, Design
of liposomes for enhanced local release of drugs by hyperthermia,
Science 202 (1978) 1290-1293.
[7] G. Kong, M.W. Dewhirst, Hyperthermia and liposomes, Int. J.
Hyperth. 15 (1999) 345-370.
[8] D. Needham, G. Anyarambhatla, G. Kong, M.W. Dewhirst, A new
temperature sensitive liposome for use with mild hyperthermia:
characterization and testing in a human tumor xenograft model, Cancer
Res. 60 (2000) 1197-1201.
[9] D. Needham, J.Y. Park, A.M. Wright J.H. Tong, Materials
characterization of the low temperature sensitive liposome (LTSL):
effects of the lipid composition (lysolipid and DSPE PEG2000) on the
thermal transition and release of doxorubicin, Faraday Discuss. 161 (2013)
515-534.
89
[10] B. Kneidl, M. Peller, G. Winter, L.H. Lindner, M. Hossann,
Thermosensitive liposomal drug delivery systems: state of the art review,
Int. J. Nanomed. 9 (2014) 4387-4398.
[11] L.M. Ickenstein, M.C. Arfvidssonc, D. Needhamd, L.D. Mayera, K.
Edwards, Disc formation in cholesterol-free liposomes during phase
transition, Biochim. Biophys. Acta. 1614 (2003) 135-138.
[12] A.G. Lee, Functional properties of biological membranes: a
physical–chemical approach, Prog. Biophys. Mol. Biol. 29 (1975) 3-56.
[13] J.K. Mills, D. Needham, Lysolipid incorporation in
dipalmitoylphosphatidylcholine bilayer membranes enhances the ion
permeability and drug release rates at the membrane phase transition,
Biochim. Biophys. Acta. 1716 (2005) 77-96.
[14] T. Tagami, M.J. Ernsting, S.D. Li, Optimization of a novel and
improved thermosensitive liposome formulated with DPPC and a Brij
surfactant using a robust in vitro system, J. Control. Release 154 (2011)
290-297.
[15] M.H. Gaber, K. Hong, S.K. Huang, D. Papahadjopoulos,
Thermosensitive sterically stabilized liposomes: formulation and in vitro
studies on mechanism of doxorubicin release by bovine serum and human
plasma, Pharm Res. 12 (1995) 1407-1416.
[16] M. Hossann, M. Wiggenhorn, A. Schwerdt, K. Wachholz, N.
Teichert, H. Eibl, R.D. Issels, L.H. Lindner, In vitro stability and content
release properties of phosphatidylglyceroglycerol containing
thermosensitive liposomes, Biochim. Biophys. Acta. 1768 (2007) 2491-
2499.
[17] L.H. Lindner, M.E. Eichhorn, H. Eibl, N. Teichert, M. Schmitt-Sody,
M. Dellian, Novel temperature-sensitive liposomes with prolonged
circulation time, Clin. Cancer Res. 10 (2004) 2168-2178.
[18] F. Guo, M. Yu, J.P. Wang, F.P. Tan, N. Li, Smart IR780 theranostic
nanocarrier for tumor-specific therapy: hyperthermia-mediated bubble-
generating and folate-targeted liposomes, ACS Appl. Mater. Interfaces 7
(2015) 20556-20567.
[19] L. Li, T.L.M. ten Hagen, D. Schipper, T.M. Wijnberg, G.C. van
Rhoon, A.M. Eggermont, L.H. Lindner, G.A. Koning, Triggered content
release from optimized stealth thermosensitive liposomes using mild
hyperthermia, J. Control. Release 143 (2010) 274-279.
[20] L. Li, T.L.M. ten Hagen, M. Hossann, R. Suss, G.C. van Rhoon,
A.M. Eggermont, D. Haemmerich, G.A. Koning, Mild hyperthermia
90
triggered doxorubicin release from optimized stealth thermosensitive
liposomes improves intratumoral drug delivery and efficacy, J. Control.
Release 168 (2013) 142-150.
[21] T. Lu, W.J.M. Lokerse, A.L.B. Seynhaeve, G.A. Koning, T.L.M. ten
Hagen, Formulation and optimization of idarubicin thermosensitive
liposomes provides ultrafast triggered release at mild hyperthermia and
improves tumor response, J. Control. Release 220 (2015) 425-437.
[22] W.J.M. Lokerse, E.C.M. Kneepkens, T.L.M. ten Hagen, A.M.M.
Eggermont, H. Grull, G.A. Koning, In depth study on thermosensitive
liposomes: Optimizing formulations for tumor specific therapy and in
vitro to in vivo relations, Biomaterials 82 (2016) 138-150.
[23] G.A. Hughes, Nanostructure-mediated drug delivery, Nanomedicine:
Nanotechnology, Biology, and Medicine 1 (2005) 22-30.
[24] R.A. Demel, S.C. Kinsky, C.B. Kinsky, L.L.M. van Deenen,
Biochim. Biophys. Acta. 150 (1968) 655-665.
[25] S. Mabrey, J.M. Sturtevant, Investigation of phase transitions of
lipids and lipid mixtures by sensitivity differential scanning calorimetry,
Proc. Natl. Acad. Sci. 73 (1976) 3862-3866.
[26] C.D. Landon, J.Y. Park, D. Needham, M.W. Dewhirst, Nanoscale
drug delivery and hyperthermia: The materials design and preclinical and
clinical testing of low temperature-sensitive liposomes used in
combination with mild hyperthermia in the treatment of local cancer,
Open Nanomed. J. 1 (2011) 38-64.
[27] H. Komatsu, S. Okada, Increase permeability of phase-separated
liposomal membranes with mixtures of ethanol-induced interdigitated and
non-interdigitated structures, Biochim. Biophys. Acta. 1237 (1995) 169-
175.
[28] G. Singhvi, M. Singh, Review: in-vitro drug release characterization
models, Int. J. Pharm. Studies Res. 2 (2011) 77-84.
[29] L. Coderch, J. Fonollosa, M. De Pera, J. Estelrich, A. De La Maza,
J.L. Parra, Influence of cholesterol on liposome fluidity by EPR
relationship with percutaneous absorption, J. Control. Release 68 (2000)
85-95.
91
Summary
Treatment of cancer has always been an important research focus. Novel
promising therapies are continually proposed, but surgery, chemotherapy
and radiotherapy are still the common treatment methods in the clinic.
These therapies, especially chemotherapy, are often accompanied by
severe side effects due to the non-selective nature of these treatment
methods. The use of nano-carriers containing chemotherapeutic
compounds is currently an important strategy to target drug delivery and
therefore reduced side-effects in healthy tissue. However, limited tumoral
accumulation of nano-carriers, insufficient drug release, and slow uptake
of the drug by cancer cells all contribute to reduced efficacy of treatment.
To deal with these limitations, thermosensitive liposomes (TSLs) are
being developed that can be triggered to locally release cargo at the tumor
site by mild local hyperthermia. The success of loading doxorubicin
(DXR) in TSLs has shown improvement of tumor drug level, drawing
increasing attention of research to formulate different doxorubicin-loaded
TSLs for a better tumor response. However, not only the composition of
the thermosensitive liposomal formulation, but also of the encapsulated
drug needs to be considered together for a better cancer treatment. The
aim of the work described in this thesis was to study and improve both
thermosensitive liposomes and drug uptake by cancer cells.
Chapter 1 introduces the background of the study and the different topics
involved in this thesis.
In Chapter 2, we developed a thermosensitive liposome formulation with
a new drug idarubicin (IDA) encapsulated. Compared to the widely used
DXR, IDA is relatively more hydrophobic and used for blood cancer in
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the clinic currently. We optimized IDA-TSL formulation to obtain the
lowest leakage at body temperature and optimal release at mild
hyperthermia (42°C) in vitro. After that, in vitro cell tests and in vivo
efficacy studies were conducted, showing improved tumor response
compared to control groups. The results demonstrate the superior
performance of IDA-loaded TSLs in treatment of cancer.
From a drug selection point of view, Chapter 3 focuses on further
investigation of IDA and DXR as encapsulated drugs in thermosensitive
liposomes. Deep and quantitative comparison of IDA-TSL and DXR-TSL
were performed with regard to in vitro release kinetics and cellular uptake
and retention, in vivo circulation and distribution, real time release
profiles inside tumor during hyperthermia and post hyperthermia,
intratumoral distribution and accumulation of released IDA and DXR,
and efficacy in tumors. These results show that IDA-TSLs give more
efficient delivery, release and tumor cellular uptake, we hypothesize to be
a consequence of hydrophobicity, thus leading to a stronger tumor
response compared to DXR-TSL.
From a TSL composition point of view, Chapter 4 investigates the
mechanism of rapid release of our thermosensitive liposomal composition.
Carboxyfluorescein (CF) was used as a model drug loaded inside TSLs
composd of different lipid ratios with and without cholesterol. We found
that proper ratios of lipid composition produces maximal release portals
in TSL membrane at phase transition temperature, which improves
triggered release under mild hyperthermia. Besides, it is not suggested to
add cholesterol due to the resulting reduced thermosensitivity.
Nowadays, thermosensitive liposome release profiles are described by
First-order mathematical models, which is used to depict the conventional,
non-thermosensitive liposome release. There is to our knowledge no
proper mathematical model to describe thermosensitive liposomal release
behaviors. Hence, in Chapter 5 we searched for a proper release equation
to describe the unique triggered release during phase transition of
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thermosensitive liposomes. After fitting with several commonly used
release models, we established an empirical equation, which shows an
optimal fitting describing the effect of release at phase transition
temperature and non-phase transition temperature as well.
Chapter 6 discusses the results of the studies in relation to the current
status of mild hyperthermia mediated thermosensitive liposomes for drug
delivery, and proposes the advice that selection of encapsulated drug and
TSL formulation need to be considered based on a rationale that produces
optimal tumoral delivery.
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Chapter 7
Dutch summary
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Samenvatting
De behandeling van kanker is altijd een belangrijke focus van onderzoek
geweest. Nieuwe veelbelovende therapieën worden voortdurend
voorgesteld, maar chirurgie, chemotherapie en radiotherapie zijn nog
steeds de belangrijkste behandelingsmethoden in de kliniek. Deze
therapieën, vooral chemotherapie, gaan vaak gepaard met ernstige
bijwerkingen vanwege het niet-selectieve karakter van deze
behandelmethoden. Het gebruik van nanodragers die
chemotherapeutische verbindingen bevatten, is momenteel een
belangrijke strategie voor gerichte medicijnafgifte en daarom
verminderde bijwerkingen in gezond weefsel. Beperkte tumorale
accumulatie van nanodragers, onvoldoende geneesmiddelafgifte ervan en
langzame opname van het geneesmiddel door kankercellen dragen
allemaal bij aan een verminderde werkzaamheid van tumorbehandeling.
Om met deze beperkingen om te gaan, worden thermogevoelige
liposomen (TSLs) ontwikkeld die kunnen worden geactiveerd om
plaatselijk lading in de tumor af te geven door milde lokale hyperthermie.
Het succes van TSLs gevuld met doxorubicine (DXR) heeft een
verbetering in intratumorale accumulatie laten zien. Hierdoor is in
vervogonderzoek naar nieuwe formuleringen voornamelijk doxorubicine
gebruikt. Wij argumenteren dat niet alleen de keuze van de
thermogevoelige liposomale formulering, maar ook van het ingekapselde
medicijn moet samen worden overwogen voor een betere
kankerbehandeling. Het doel van het werk onderzoek beschreven in dit
proefschrift was het bestuderen en verbeteren van thermogevoelige
liposomen om opname van geneesmiddelen door kankercellen te
verbeteren.
Hoofdstuk 1 introduceert de achtergrond van de studie en de
verschillende onderwerpen die bij dit proefschrift zijn betrokken.
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In hoofdstuk 2 ontwikkelden we een thermogevoelige
liposoomformulering met een nieuw medicijn idarubicine (IDA)
ingekapseld. Vergeleken met de veel gebruikte DXR is IDA relatief meer
hydrofoob en wordt het momenteel gebruikt voor de behandeling van
bloedkanker in de kliniek. We hebben de IDA-TSL-formulering
geoptimaliseerd om de laagste lekkage bij lichaamstemperatuur en
optimale afgifte bij milde hyperthermie (42 °C) in vitro te verkrijgen.
Daarna werden in vitro en in vivo studies uitgevoerd, die een verbeterde
tumorrespons aantoonden voor IDA-TSL in vergelijking met DXR-TSL
en controlegroepen. De resultaten demonstreren de haalbaarheid van het
formuleren van de nieuwe met IDA beladen TSL’s om tumor te
behandelen.
Vanuit het oogpunt van drugkeuze richt hoofdstuk 3 zich op verder
onderzoek van IDA en DXR als geneesmiddelen ingekapseld in
thermogevoelige liposomen. Diepe en kwantitatieve vergelijking van
IDA-TSL en DXR-TSL werd uitgevoerd met betrekking tot hun in vitro
afgiftekinetiek en cellulaire opname en retentie, in vivo circulatie en
distributie, real-time afgifteprofielen in tumor tijdens hyperthermie en
post-hyperthermie, intratumorale distributie en accumulatie van
afgegeven IDA en DXR en werkzaamheid in tumoren. Deze resultaten
tonen aan dat IDA-TSL een efficiëntere aflevering, afgifte en
tumorcellulaire opname, mogelijk als gevolg van hydrofobiciteit,
verschaft, hetgeen aldus leidt tot een sterkere tumorrespons in
vergelijking met DXR-TSL.
Vanuit een gezichtspunt van TSL-samenstelling, onderzoekt Hoofdstuk 4
het mechanisme van snelle afgifte van onze thermogevoelige liposomale
samenstelling. Carboxyfluoresceïne (CF) werd gebruikt als een
modelgeneesmiddel geladen in TSL samengesteld uit verschillende
lipideverhoudingen, met en zonder cholesterol. We zagen dat de juiste
verhoudingen van de lipidensamenstelling maximale afgifteportalen in het
TSL-membraan bij de fase-overgangstemperatuur produceren, wat de
geactiveerde afgifte onder milde hyperthermie verbetert. Bovendien
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wordt toevoeging van cholesterol afgeraden aangezien hiermee de
thermosensibiliteit vermindert.
Tegenwoordig worden thermogevoelige liposoomafgifteprofielen
beschreven door wiskundige modellen van de eerste orde die worden
gebruikt om afgifteprofielen te beschrijven van conventionele niet-
thermisch gevoelige liposomen. Er is, zo ver wij weten, geen goed
wiskundig model beschikbaar om afgifte van stoffen door
thermogevoelige liposomen te beschrijven. Daarom hebben we in
hoofdstuk 5 gezocht naar een goede vergelijking om deze unieke,
getriggerde afgifte tijdens faseovergang van warmtegevoelige liposomen
te beschrijven. Na veelgebruikte afgiftemodellen te hebben getoets,
hebben we een empirische vergelijking opgesteld, die een optimaal
passend fit laat zien voor afgifte bij faseovergangstemperatuur en niet-
faseovergangstemperatuur.
Hoofdstuk 6 bespreekt de resultaten van de studies hier gepresenteerd met
betrekking tot de huidige status van temperatuurgevoelige nano-carriers.
Tevens wordt de conclusie bereikt dat naast het vinden van nieuwe
formuleringen ook de keuze van het chemotherapeuticum moet worden
bepaald met de realisatie dat optimale afgifte, verdeling in de tumor en
opname door tumorcellen leidend zijn.
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